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The single centre randomised trial aimed to assess whether right ventricular 
outflow tract (RVOT) compared to right ventricular apical (RVA) pacing is more 
beneficial at the medium term follow-up.
Fifty patients were randomised to either RVA (n—25) or RVOT (n=25) pacing. 
Baseline and 6 month follow-up investigations included: electrocardiogram, New 
York heart failure functional (NYHA) class, Minnesota Living with Heart 
Failure (MLWHF) score. Short Form-36 health survey (SF-36), echocardiogram, 
and a cardiopulmonary exercise test. The primary endpoint was peak oxygen 
consumption (PVO2). Secondary endpoints were: NYHA class, MLWHF and 
SF-36 scores, LVEF, and dyssynchrony criteria.
There were no significant differences in changes in PVO2 levels between the 
study groups. Similarly, QRS duration changes were not significantly different 
between the study groups. In contrast, MLWHF scores improved significantly in 
the RVOT group (32 ± 19) compared with the RVA group (21 ± 22), P=0.041. In 
addition, SF-36 health survey indicated better scores in RVOT patients in the 
following areas: (1) Physical Function, 36.6 ± 28.0 (RVOT) versus 11.2 ± 26.0 
(RVA), P = 0.005; (2) Role Limitation due to Emotional Problem scores, 43.3 ± 
9.7 (RVOT) versus 4.5 ±11.6 (RVA arm), P = 0.016; (3) Vitality Energy Fatigue 
scores 26.3 ± 27.0 (RVOT) versus 7.2 ± 24.0 (RVA), P = 0.024. Echocardiogram 
data were not significantly different between the groups.
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Within the limits of this study, RYOT pacing was not superior to RVA in terms 
of PVO2 and echocardiogram parameters. However, RYOT pacing apparently 
offered a significant improvement in some health-related quality of life scores. 
Larger multi-centre randomised studies with a longer follow-up are now 
indicated.
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CHAPTER ONE
Introduction
Foreword
The right ventricular apex (RVA) has been the elective site for placing 
endocardial pacing leads since 1959 when Seymour Furman described the use of 
the transvenous route for pacemaker implantation (Furman & Schwedel 1959). 
Although, review of the X- ray following Furman’s implant in fact demonstrates 
the lead to be within the basal septum. The RVA has subsequently been used 
because it is easily accessible, readily identified, and associated with a stable 
position and reliable chronic pacing parameters. It was recognised, however, that 
pacing from the RVA did not reproduce normal ventricular conduction or 
contraction. With the advent of reliable active fixation leads, alternative right 
ventricular sites became accessible and began to be explored. In this thesis 
introduction, the detrimental effects of RVA pacing will be outlined, the right 
ventricular outflow tract (RVOT) will be defined, and the evidence for selective 
site pacing (SSP) will be discussed.
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1.1. Anatomy of the conduction system
1.1.1 Sinoatrial node
The sinoatrial (SA) node is a subepicardial structure located at the junction of the 
right atrium and superior vena cava. It has abundant autonomic innervation and a 
copious blood supply; it is often located within the adventitia of the large SA 
nodal artery, a proximal branch of the right coronary artery (55%), or the left 
circumflex coronary artery. Histologically, the SA node consists of a dense 
framework of collagen that contains a variety of cells, among them the large, 
centrally located P cells, which are thought to initiate impulses; transitional cells, 
intermediate in structure between P cells and regular atrial myocardial cells; and 
Purkinj e-like fibre tracts, extending through the perinodal area and into the 
atrium.
1.1.2 Atrioventricular node
The atrioventricular (AV) node is a small subendocardial structure within the 
interatrial septum located at the convergence of the specialised conduction tracts 
that course through the atria. Like the SA node, the atrioventricular node has 
extensive autonomic innervation and an abundant blood supply from the large 
atrioventricular nodal artery, a branch of the right coronary artery in 90% of 
cases, and also from septal branches of the left anterior descending coronary 
artery. Histologic examination of the AVN reveals a variety of cells embedded in 
a loose collagenous network including P cells (although not nearly as many as in 
the SA node), atrial transitional cells, ordinary myocardial cells, and Purkinje 
cells.
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1.1.3 His bundle
Purkinje fibres emerging from the area of the distal atrioventricular node 
converge gradually to form the His bundle, a narrow tubular structure that runs 
through the membranous septum to the crest of the muscular septum, where it 
divides into the bundle branches. The His bundle has relatively sparse autonomic 
innervation, although its blood supply is quite ample, emanating from both the 
AV nodal artery and septal branches of the left anterior descending artery. 
Longitudinal strands of Purkinje fibres, divided into separate parallel 
compartments by a collagenous skeleton, can be discerned by histologic 
examination of the His bundle. Relatively sparse P cells can also be identified, 
embedded within the collagen.
1.1.4 Bundle branches
The bundle branch system is an enormously complex network of interlacing 
Purkinje fibres that varies greatly among individuals. It generally starts as one or 
more large fibre bands that split and fan out across the ventricles until they 
finally terminate in a Purkinje network that interfaces with the myocardium. In 
some cases, the bundle branches clearly conform to a trifascicular or 
quadrifascicular system. In other cases, however, detailed dissection of the 
conduction system has failed to delineate separate fascicles. The right bundle is 
usually a single, discrete structure that extends down the right side of the 
interventricular septum to the base of the anterior papillary muscle, where it 
divides into three or more branches. The left bundle more commonly originates 
as a very broad band of interlacing fibres that spread out over the left ventricle, 
sometimes in two or three distinct fibre tracts. There is relatively little autonomic
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innervation of the bundle branch system, but the blood supply is extensive, with 
most areas receiving branches from both the right and left coronary systems.
1.2 Physiological background
1.2.1 The normal physiology of the conduction system and 
ventricular activation
The SA node has the highest rate of spontaneous depolarisation (automaticity) in 
the specialised conduction system, and under ordinary circumstances, it is the 
major generator of impulses. Its unique location astride the large SA nodal artery 
provides an ideal milieu for continuous monitoring and instantaneous adjustment 
of heart rate to meet the changing metabolic needs of the body. The SA node is 
connected to the AV node by several specialised fibre tracts, the function of 
which has not been fully elucidated. The AV node appeal's to have three major 
functions: It delays the passing impulse for approximately 0.04 seconds under 
normal circumstances, permitting complete atrial emptying with appropriate 
loading of the ventricle; it serves as a subsidiary impulse generator, as its 
concentration of P cells is second only to that of the SA node; and it acts as a 
type of filter, limiting ventricular rates in the event of an atrial tachyarrhythmia. 
His bundle arises from the convergence of Purkinje fibres from the AV node, 
although the exact point at which the AV node ends and the His bundle begins 
has not been delineated either anatomically or electrically. The separation of the 
His bundle into longitudinally distinct compartments by the collagenous 
framework allows for longitudinal dissociation of electrical impulses. Thus, a 
localised lesion below the bifurcation of the His bundle (into the bundle 
branches) may cause a specific conduction defect (e.g., left anterior fascicular
15
block). The bundle branches arise as a direct continuation of the His bundle 
fibres. Disease within any aspect of the His bundle branch system may cause 
conduction defects that can affect AY synchrony or prevent synchronous right 
and left ventricular activation. The electrical activation wavefronts first exit to 
the LV endocardial cavity at the lower interventricular septum and then 
propagate in an apicobasal direction because the initial portion of the His- 
Purkinje system is electrically insulated from the surrounding contractile 
ventricular myocardium. As a result, the mechanical contraction begins at the 
apex and progresses upward to eject blood into the aorta. The high conduction 
velocity of cardiac electrical impulses through the His-Purkinje conduction 
system (3-4 m/s) ensures rapid and synchronised depolarisation of ventricular 
myocardium that is essential for effective blood pumping. As demonstrated in the 
perfused isolated human heart (Durrer et al. 1970), the electrical activation of the 
LV starts synchronously (within 5 milliseconds) at 3 endocardial areas (the 
anterior paraseptal wall, the left surface of the mid-interventricular septum, and 
the posterior paraseptal wall about one third the distance from apex to base) and 
envelops nearly the whole LV endocardial cavity 30 milliseconds after the onset 
of ventricular activation, except the latest activated regions at the inferior and/or 
posterobasal area. Electrical activation of the whole left ventricle completes 
within 80 milliseconds. A similar LV electrical activation sequence has also 
been observed in patients undergoing endocardial catheter mapping (Cassidy et 
al. 1984). This normal and rapid electrical activation sequence of the left 
ventricle is essential for synchronous and coordinated myocardial contraction for 
optimal LV performance.
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1.2.2 Pathophysiology of abnormal ventricular activation
1.2.2.1 Adverse haemodynamic effects of left bundle branch block
The normal physiologic electrical activation of the left ventricle can be disrupted
in patients with structural heart diseases, such as dilated cardiomyopathy, as 
manifested by the occurrence of intraventricular conduction defect with left 
bundle branch block (LBBB) and/or widening of QRS duration. During LBBB, 
the ventricular activation starts in the right ventricle, and the left ventricle is 
activated by a slow right-to-left transseptal conduction, which then propagates 
into the LV cavity at the middle third and/or the apical third of the LV septum 
before spreading through the whole LV cavity (Vassallo et al. 1984). Because 
this propagation of electrical impulses in LBBB is primarily through the slowly 
conducting myocardium (0.3-1 m/s) instead of the His-Purkinje system, the total 
LV activation time is prolonged. This abnormal electrical activation sequence 
leads to LV mechanical dyssynchrony with inefficient cardiac performance due 
to internal transfer of work between the early and late activated region of the 
chamber (Prinzen et al. 1999). In fact, cardiac functional abnormality, including 
prolonged LV isovolumetric contraction and relaxation times, abbreviation of LV 
filling, and RV-LV asynchrony in systole and diastole have been demonstrated in 
patients with LBBB (Grilles et al. 1989). More importantly, the presence of 
LBBB has been shown to be an independent predictor of cardiac mortality and 
morbidity in patients with systolic heart failure (Baldasseroni et al. 2002).
1.2.2.2 Adverse haemodynamic effects of right ventricular apical pacing
During RV apical pacing, the surface electrocardiogram pattern simulates that of 
spontaneous LBBB. Similar to LBBB, the LV activation during RV apical
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pacing initiates with slow transseptal activation through the myocardium and 
then exits to the LV endocardial cavity at the interventricular septum. However, 
it has been postulated that after exiting into the left ventricle, the paced 
wavefronts may reengage the intact distal Purkinje system with a more rapid LY 
depolarisation to activate the rest of the left ventricle (Wyndham et al. 1980). 
Nonetheless, the latest activated region has consistently been the inferolateral 
base during RV apical pacing. Adverse haemodynamic effects of RV apical 
pacing have been long recognised in the mammalian heart and the animal model 
(Prinzen Sc Peschar 2002). The authors demonstrated that in canine hearts with 
experimental LBBB, LV pacing significantly improves left ventricular pump 
function. Similarly, Burkhoff et al demonstrated that the LV contractile strength 
changes with the sites of ventricular pacing and shows a linear inverse 
relationship between the changes in QRS duration (Burkhoff, Oikawa, Sc Sagawa 
1986). In experimental and clinical studies, there is a rightward shift of the 
pressure-volume relationship during the LV end-systolic phase, and the left 
ventricle operates at a larger volume during RV apical pacing (Prinzen Sc Peschar 
2002). These acute haemodynamic changes are associated with a decrease in 
both LV stroke volume and the maximal rate of rise in LV pressure (+dP/dt). 
Furthermore, both short-term and long-term clinical studies have demonstrated a 
reduction of LV ejection fraction (LVEF) by 5% to 10% with RV apical pacing 
(Tse et al. 2002). In addition, RV apical pacing may also lead to impairment of 
diastolic function with a reduction of diastolic filling time and maximal rate of 
fall of LV pressure (-dP/dt). Several mechanisms (Fig 1.1) have been proposed 
for the mechanical inefficiency during abnormal LV electrical activation and 
contraction during RV pacing (Sweeney Sc Prinzen 2006). First, the early
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activated portion of LV close to the pacing site contracts at low chamber pressure 
and stretches the opposing non-contracting wall. This stretching causes an 
increased force of contraction because of the local Frank-Starling mechanism and 
further delays the shortening of the late activated portion of the LV. As a result, 
the late activated portion elicits contraction at higher wall stress because the early 
activated region is in a period of systolic stiffening and imposes loading on the 
early activated portion. This reciprocated stretching and contraction of opposing 
LV walls leads to wasting of energy because of internal transfer of mechanical 
work and inefficient contraction. Indeed, recent advances in echocardiographic 
technique with tissue Doppler imaging have provided further insight to the 
occurrence of LV dyssynchrony after RV pacing. In patients with congenital AV 
block or iatrogenic AV block after AV nodal ablation for atrial fibrillation (Tops 
et al. 2006), a substantial proportion of patients developed new onset 
echocardiographic evidence of intra- and/or interventricular dyssynchrony, which 
was associated with deterioration of LV function. Second, the changes in LV 
contraction pattern during RV apical pacing result in redistribution of regional 
myocardial mechanical work and perfusion. In experimental study (Lee et al. 
1994), regional myocardial oxygen consumption and perfusion at the early 
activated region near the pacing site are decreased because of a reduction in 
mechanical loading. Similarly, clinical studies have demonstrated a reduction in 
regional LVEF at the site of stimulation and the presence of perfusion defects in 
up to two thirds of RV apically paced patients without any significant coronary 
artery disease (Tse et al. 2002). Interestingly, the change in coronary perfusion 
at the pacing site is reversible upon cessation of pacing.
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Figure 1.1: Proposed mechanisms for the adverse effects on ventricular function 
and remodelling with RV apical pacing (Sweeney & Prinzen 2006).
Third, experimental studies have shown that prolonged RV apical pacing leads to 
asymmetric LV hypertrophy and ventricular remodelling with LV dilatation 
(Prinzen et al. 1995; van Oosterhout et al. 2001). Asynchronous LV activation 
causes hypertrophy over the late activated portion of the left ventricle because of 
an increase in local mechanical loading due to prestretching by the early 
activated portion. In addition, redistribution of sympathetic innervations after RV 
pacing also contributes to asymmetrical LV hypertrophy due to a local increase 
in catecholamine release (Lee et al. 1994). Furthermore, pronounced histologic 
changes with myofibrillar disarray, dystrophic calcification, and disorganised 
mitochondria have been observed after RV apical pacing (Karpawich et al. 
1990). Finally, mitral regurgitation has been observed after chronic RV apical 
pacing, in rare occasions, necessitating mitral valvular replacement (Le, Klug, &
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Lacroix 1996). Indeed, Chen et al have recently reported that new onset or 
worsening of mitral regurgitation can be observed in a significant proportion of 
patients after chronic RV apical pacing. Maurer et al have demonstrated that RV 
apical pacing can induce mitral regurgitation in a canine model of RV pacing 
(Maurer et al. 1984). Although the mechanisms remain unclear, it has been 
postulated that a reduction of the trans-mitral pressure gradient and increased 
papillary muscle tethering forces due to LV remodelling and desynchronised 
papillary muscle contraction may contribute to the development of mitral 
regurgitation after RV apical pacing. In patients with HF and LBBB, the 
reduction in mitral regurgitation after cardiac resynchronisation therapy is 
associated with an increased transmitral pressure gradient (the closing force) due 
to more coordinated LV contraction (Breithardt et al. 2003). Furthermore, 
Kanzaki et al have demonstrated in a similar cohort of patients with HF that the 
reduction in the fraction of mitral regurgitation is significantly correlated with 
shortening of interpapillary muscle time delay, suggesting that papillary muscle 
dyssynchrony may contribute to the development of mitral regurgitation 
(Kanzaki et al. 2004).
1.2.2.3 Optimal choice of pacing site to preserve left ventricular function
In patients with low-degree or intermittent AV conduction abnormalities, the use 
of minimal pacing modes can significantly reduce the percentage of ventricular 
pacing. However, in those patients who have high-degree AV block, reducing 
the percentage of ventricular pacing is not feasible, and alternative ventricular 
pacing sites other than RV apical may result in a better cardiac performance. The 
ideal alternative ventricular pacing site should be a single site located in the right
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ventricle that can be easily and safely achieved, should have similar long-term 
lead stability, sensing, and pacing threshold as RV apical pacing, and is without 
additional risk and cost.
RV outflow tract/RV septal pacing sites are the most studied alternative RV sites 
for permanent pacing. Interestingly, RV outflow tract was the first reported site 
of pacing used in the human implant of the endocardial pacing lead. RV pacing 
sites other than RV apex were not commonly used until the recent advances in 
the use of active fixation endocardial lead systems. For practical consideration, 
RV outflow tract/septal pacing is not inferior to RV apical pacing, in terms of 
long-term stability, feasibility, and efficacy, and appeal’s to be associated with a 
low risk of RV perforation and diaphragmatic stimulation, and easy to extract. 
Furthermore, it is may be that pacing at the septal aspect of the RV outflow tract 
results in a shorter LV activation time and possibly less ventricular 
dyssynchrony. However, there are significant discrepancies in the published data 
concerning the potential benefits of RV outflow tract/septal pacing over RV 
apical pacing (Tse et al. 2002). Two potential reasons for the differing results 
may be related to imprecise definitions of RV outflow tract/septal pacing sites 
and the duration of follow-up in those studies. Laske et al studied pacing 
performance in swine hearts and suggested that pacing at the RV mid-septum 
region is required to stimulate the interventricular conduction system to cause a 
more synchronous ventricular activation pattern (Laske et al. 2006), Furthermore, 
the adverse LV remodelling effect of RV apical pacing may take a longer period 
to manifest, especially in patients with normal LVEF. As a result, only clinical 
studies with more precise definition of the RV outflow tract pacing site and a 
long duration of follow-up (>6 months) showed that RV septal pacing preserved
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LV function (Victor et al. 2006), One of the major issues related to RV septal 
pacing is to define the optimal site for lead placement in the septum. Most 
published studies defined the RV septal region by fluoroscopy. On the other 
hand, a more synchronous ventricular activation pattern during RV septal pacing 
can be reflected by a narrow QRS duration. Indeed, a shorter paced QRS 
duration has been shown to correlate with better LVEF during the acute pacing 
phase (Schwaab et al 1999). Therefore, it is likely that, other than the use of 
fluoroscopic landmarks, the use of additional parameters, such as paced QRS 
width or morphology or echocardiographic indexes, is needed to define optimal 
RV septal pacing sites.
1.3 History of cardiac pacing
In 1899, J A McWilliam reported in the British Medical Journal his experiments 
in which application of an electrical impulse to the human heart in asystole 
caused a ventricular contraction and that a heart rhythm of 60-70 beats per 
minute could be evoked by impulses applied at intervals equal to 60-70/minute. 
In 1932, the American physiologist Albert Hyman, working independently, 
described an electro-mechanical instrument of his own, powered by a spring- 
wound hand-cranked motor. Hyman himself referred to his invention as an 
"artificial pacemaker", the term continuing in use to this day. An external 
pacemaker was designed and built by the Canadian electrical engineer John 
Hopps in 1950. This was a substantial external device using vacuum tube 
technology to provide transcutaneous pacing. It was somewhat crude and painful 
to the patient in use and, being powered from an AC wall socket, carried a
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potential hazard of electrocution of the patient by inducing ventricular 
fibrillation. A number of innovators, including Paul Zoll, made smaller but still 
bulky transcutaneous pacing devices in the following years using a large 
rechargeable battery as the power supply. In 1957, engineer Earl Bakken of 
Minneapolis, Minnesota, produced the first wearable external pacemaker. This 
pacemaker, housed in a small plastic box, had controls to permit adjustment of 
pacing heart rate and output voltage and was connected to electrode leads which 
passed through the skin of the patient to terminate in electrodes attached to the 
surface of the myocardium of the heart. The first clinical implantation into a 
human of a fully implantable pacemaker was in 1958 at the Karolinska Institute 
in Solna, Sweden, using a pacemaker designed by Rune Elmqvist Surgeon Ake 
Senning connected electrodes attached to the myocardium of the heart by 
thoracotomy. The device failed after three hours. A second device was then 
implanted which lasted for two days. The world's first implantable pacemaker 
patient, Arne Larsson, went on to receive 26 different pacemakers during his 
lifetime. He died in 2001, at the age of 86. In 1959, temporary transvenous 
pacing was first demonstrated by Furman et al. in which the catheter electrode 
was inserted via the patient's basilic vein (Furman et al. 1959). The first use of 
transvenous pacing in conjunction with an implanted pacemaker was by 
Parsonnet in the USA, Lagergren in Sweden and Jean-Jaques Welti in France in 
1962-63. The transvenous, or per-venous, procedure involved incision of a vein 
into which was inserted the catheter electrode lead under fluoroscopic guidance, 
until it was lodged within the trabeculae of the right ventricle. This method was 
to become the method of choice by the mid-1960s. In the late 1960s, several 
companies, including ARCO in the USA, developed isotope powered
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pacemakers, but this development was overtaken by the development in 1971 of 
the lithium-iodide cell by Wilson Greatbatch. Lithium-iodide or lithium anode 
cells became the standard for future pacemaker designs.
At present, pacemakers are implanted in a variety of patients. The primary 
purpose of a pacemaker is to maintain an adequate heart rate, either because the 
heart's native pacemaker is not fast enough, or there is a block in the heart's 
electrical conduction system. Modern pacemakers are externally programmable 
and allow the cardiologist to select the optimum pacing modes for individual 
patients. Some combine a pacemaker and defibrillator in a single implantable 
device. Others have multiple electrodes stimulating differing positions within the 
heart to improve synchronisation of the lower chambers of the heart.
1.4 Indications for permanent cardiac pacing
In the early days of pacing, atrioventricular (AV) block was the most common 
conduction disorder for which a pacemaker was prescribed. While indications 
have expanded considerably, AY block remains one of the main indications for 
permanent pacing. There are different types of AV block which must be 
considered as a progressive disorder that delays and ultimately blocks conduction 
of the electrical impulse through the AV node into the ventricle. First degree AV 
block occurs when the electrical signal gets delayed at the AV node before it can 
pass to the ventricles. This manifests on the surface EGG as an abnormally long 
PR interval. First degree AV block is most probably benign and patients are 
usually asymptomatic. There are two types of second degree AV block. Type I
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second degree AV block (also called Mobitz I or Wenckebach) is characterised 
by a progressive prolongation of PR interval before a blocked beat. It is usually 
benign but pacing can be considered if accompanied by documented symptoms. 
Type II second degree AV block (also called Mobitz II) is characterised by a 
stable PR interval and a periodic missing of QRS complex. Pacing should be 
considered if documented symptoms are present. In third degree AV block (also 
called complete heart block), impulses do not travel through the AV node. 
Therefore, the ventricles beat independently from atrial activity (atrioventricular 
dissociation). Pacing is indicated for these patients, even in the absence of 
symptoms as it provides prognostic as well as symptomatic benefits. Nowadays, 
sinus node dysfunction (also called sick sinus syndrome or SSS) is the most 
common arrhythmic constellation that indicates pacing. It describes sinus 
bradycardia, sinus arrest, sinoatrial block, and tachy-brady syndrome. Sinus node 
dysfunction is a clear indication for pacing only when associated with 
documented symptoms. Pacing in this category of patients provides symptomatic 
but not prognostic benefits. There are other less common indications for pacing 
such as carotid sinus syndrome or pacing to prevent certain arrhythmias. The 
decision to implant a permanent pacemaker is an important one and should be 
based on solid clinical evidence. The joint committee of the American College of 
Cardiology and the American Heart Association was formed in the 1980s to 
provide uniform criteria for pacemaker implantation. These guidelines were first 
published in 1984 and most recently revised in 2008 in conjunction with the 
Heart Rhythm Society (Epstein et al. 2008).
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1.5 Quality of life and functional status following 
pacemaker implantation
Despite the fact that the number of indications for implantation of cardiac 
pacemakers is still increasing, most of these devices are implanted to prevent 
bradyarrhythmias due to disorders of the sinus node or of the specific cardiac 
conduction system. In the 1950s, pacemaker therapy was introduced with a main 
objective to improve survival. The subsequent introduction of atrioventricular 
synchronous pacemakers (DDD, AAI) and ventricular rate adaptive pacemakers 
(VVIR) showed improved haemodynamics and maximal exercise capacity 
compared to the former introduced fixed rate ventricular pacemakers (VVI). 
Efficiency of these more sophisticated pacemaker therapies can be defined as the 
relationship between the benefits of these pacemaker therapies, as represented by 
survival and quality-of-life (QOL), and the costs associated with them (Gribbin 
et al. 2004). Few pacemaker recipients perform vigorous exercise in daily life, 
comparable to maximal exercise capacity, one of the parameters used to evaluate 
these benefits in previous studies. Therefore, this clinical outcome parameter 
may be of little value as an indicator of a patients' QOL and efficiency of 
pacemaker therapy. Subjective cardiovascular symptoms and patients' perceived 
health might provide a better measure of the value of a certain kind of 
stimulation method ("pacing mode"). Hence, assessment of QOL is of increasing 
importance in the evaluation of pacing modes, especially in this era of 
sophisticated pacing devices and the associated escalating costs. Implantation of 
a more expensive device should be objectively and subjectively justified and 
beneficial. The expanding interest in QOL has led to a wide range of 
questionnaires.
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The decision of which instrument to use may be based on several criteria 
(Stofmeel et al. 2000). First, it is important that a questionnaire measures what it 
is supposed to. This is defined as its validity. The key question is if the scale is 
valid for a particular application in a specific population. The assessment of 
validity commonly begins with content validity; do the selected items reflect the 
study object? A first approach to establish content validity is to ask patients and 
experts in the field to critically review the content of the scale. Next, more formal 
statistical procedures are used to test criterion and construct validity. Criterion 
validity indicates the effectiveness of a test in predicting an individual's standing 
on some outcome or criterion. Scores on a health related QOL questionnaire 
might be compared to objective measures of cardiac functioning (e.g., New York 
Heart Association [NYHA] classification, 6-minute walking distance). Construct 
validity is the extent to which a theoretical construct or trait is measured by a 
test. In multidimensional questionnaires, it is important to examine if each scale 
of the questionnaires reliably measures a distinct aspect of health. In addition, 
inspection of correlations with similar (convergent) and dissimilar (discriminate) 
measures constitute evidence that the test measures this theoretical construct. 
Second, it is important to evaluate if a questionnaire can reproduce similar scores 
within one subject under the same circumstances. This is called reliability of a 
questionnaire. More formal, reliability is defined as the proportion of observed 
variation in scores that reflects actual variation in health levels. Two types of 
reliability are distinguished: inter-rater agreement or observer variation (do 
different raters obtain the same result in the same individual) and test-retest 
reliability (is the equal result obtained on a second assessment of the same
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patient). Finally, it is useful to check if a selected questionnaire was previously 
used in a study with a similar population to judge the feasibility and to allow 
comparisons to other research.
Quality of life measures of pacemaker patients were appraised by Stofmeel et al 
(Stofmeel et al. 2000). They searched MEDLINE (1985-1998) for studies 
assessing quality-of-life in general and in pacemaker patients. This search 
resulted in 65 studies. From these 65 studies, 14 studies using multi-item 
questionnaires for evaluating QOL in DDD pacing compared to VVIR pacing 
were selected for review. In this paper, they found that the SF-36 appears to be 
the best among generic questionnaires because of its psychometric characteristics 
and experience of use. Concerning disease specific instruments, many quality of 
life questionnaires lack rigorous psychometric validation, which constitutes a 
serious limitation. Previous studies suggested that implantation of 
atrioventricular pacemakers improves quality-of-life compared to ventricular 
pacemakers, but since no well-designed and validated questionnaire exists, these 
results should be interpreted with caution. The best outcome measure to evaluate 
quality-of-life in pacemaker patients would be a combination of a generic health 
profile with established reliability and validity supplemented with a 
cardiovascular assessment adjusted to suit pacemaker patients, By doing so, 
individual scores can be compared within a disease cohort and to same-aged, non 
diseased persons, as well as other diseased populations. They recommended that 
the development and validation of such an instrument is needed.
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Both dual chamber and rate adaptive single chamber pacing have been shown to 
offer benefits compared with fixed rate ventricular pacing in terms of improved 
haemodynamics, increased treadmill exercise tolerance, and reduced symptoms; 
however, it is not clear to what extent these changes translate in to clinical 
benefit for the typical patient (Toff et ah 1997). Quality of life studies have 
shown conflicting results although there is considerable evidence of patient 
preference for physiological pacing modes. Much of the clinical data supporting 
the use of physiological pacing is derived from short term studies of relatively 
small numbers of patients, often younger than the average. In many instances, 
crossover study designs have been used in patients who have already been fitted 
with physiological pacing systems and who were, presumably, pre-selected as 
being more likely to benefit from them (Toff et al. 1997). The United Kingdom 
Pacing and Cardiovascular Events (UKPACE) trial (Toff et al. 2005). was a 
multicenter, randomised, parallel-group trial, 2021 patients 70 years of age or 
older who were undergoing their first pacemaker implant for high-grade 
atrioventricular block were randomly assigned to receive a single-chamber 
ventricular pacemaker (1009 patients) or a dual-chamber pacemaker (1012 
patients). In the single-chamber group, patients were randomly assigned to 
receive either fixed-rate pacing (504 patients) or rate-adaptive pacing (505 
patients). The primary outcome was death from all causes. Secondary outcomes 
included atrial fibrillation, heart failure, and a composite of stroke, transient 
ischemic attack, or other thromboembolism. The quality of life was assessed 
using a composite questionnaire comprising two widely used generic 
instruments, the SF-36 and the EuroQoL EQ-5D. These were selected as they 
were considered reliable and well validated, with ample normative data, and they
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can both be administered within a few minutes by personnel with minimal 
training. The median follow-up period was 4.6 years for mortality and 3 years for 
other cardiovascular events. The mean annual mortality rate was 7.2 % in the 
single-chamber group and 7.4 % in the dual-chamber group (hazard ratio, 0.96; 
95 % confidence interval, 0.83 to 1.11). They found no significant differences 
between the group with single-chamber pacing and that with dual-chamber 
pacing in the rates of atrial fibrillation, heart failure, or a composite of stroke, 
transient ischemic attack, or other thromboembolism. They concluded that in 
elderly patients with high-grade atrioventricular block, the pacing mode does not 
influence the rate of death from all causes during the first five years or the 
incidence of cardiovascular events during the first three years after implantation.
One of the most commonly used QOL measures is the Minnesota living with 
heart failure (MLWHF) questionnaire (Bennett et al. 2002 & Rector et al. 1987). 
It is used in a completely different cohort to patients requiring pacing as a 
treatment for bradyarrhythmias. As indicated by its name, MLWHF is mainly 
used in patients with heart failure to measure their response to either medical or 
device intervention. It was used in the majority of trials on biventricular pacing 
such as the MIRACLE study (Abraham et al. 2002) and the CARE-HF study 
(Cleland et al. 2005). Despite its wide use, the validity of the MLWHF as a 
measure of therapeutic response was questioned in some studies (Rector et al. 
1987).
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1.6 Peak oxygen consumption as a measure of exercise 
capacity and cardiac function
Physical disability has the potential to reduce an individual’s quality of life. 
Objective evaluation of functional capacity can thus be used to categorise the 
relative severity of any pathological condition. It can also be used to provide 
prognostic information and quantitative assessment of therapeutic interventions. 
In cardiac dysfunction secondary to any cause and in the absence of other organ 
or system dysfunction, it may provide indirect information about the extent of 
cardiac function. In practical terms, any test of function should be available, cost 
effective and acceptable to the subject under evaluation. In scientific terms it 
must be representative, validated and reproducible. At present no index of 
functional capacity completely fulfils all the above criteria. Due to the high 
incidence of heart disease and the level of functional disability exhibited by 
cardiac patients, much of the research into functional capacity has concentrated 
on this subgroup of the patient population. Despite complex central and 
peripheral compensatory mechanisms, it is important to recognise that the initial 
insult is to the heart itself. It is therefore logical to evaluate the heart directly, but 
to consider it in the broader context of circulatory homeostasis.
In healthy subjects, cardiac output (1/min), and heart rate (beats/min), increase 
linearly with increasing work rate (Donald et al. 1955). Work rate, is measured in 
“METS” (metabolic equivalents) and is derived from the average resting oxygen 
consumption for a 70 kg, 40-year-old man. It is equal to 3.5 ml/min per kilogram. 
Systolic blood pressure (mmHg) also increases during incremental exertion, as 
does diastolic pressure, though to a lesser extent (Donald et al. 1955). Oxygen
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consumption (VO2 in ml/min) depends on the combined processes of pulmonary 
ventilation and respiratory gas diffusion, cardiac output, and skeletal muscle 
oxygen utilisation. When describing VO2, normalisation is usually made using 
body mass (ml/kg/min). The relationship between VO2 and work rate is initially 
linear until a point is reached where further increments in work are accompanied 
by a constant rate of oxygen consumption (Albouaini et al. 2007). This is known 
as the maximal oxygen consumption and care should be taken to distinguish this 
from peak oxygen consumption, which represents the highest achievable value 
during a test. A plateau response is rarely seen except in very determined 
subjects such as trained athletes. Carbon dioxide production (VCO2 in ml/min) 
initially increases slowly relative to VO2 due to metabolism of available 
substrates and the greater solubility of carbon dioxide in tissue. It subsequently 
increases as dictated by the ratio of the time constants of VCO2 and VO2, known 
as the respiratory exchange ratio (RER). If lactic acidosis occurs during exercise 
due to the onset or progression of anaerobic metabolism, VCO2 increases faster 
than VO2 because of the additional carbon dioxide produced during the buffering 
of bicarbonate. At this point the subject exceeds their anaerobic threshold. As 
exercise continues the respiratory exchange ratio exceeds the value of 1.0. 
Minute ventilation (VE in 1/min) depicts the volume of air inspired in one minute 
and mirrors the response of VCO2 (Ross 2003). Ventilatory equivalents for 
oxygen (VE/VO2) and carbon dioxide (VE/VCO2) represent the ratios of minute 
ventilation to each gas respectively, and are regarded as markers of respiratory 
effort for given levels of gas exchange. Metabolic activity in skeletal muscle 
increases during exertion, necessitating an improvement in limb blood flow, 
which is achieved by an increase in cardiac output, perfusion pressures and local
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vasodilatation. Exercise testing is employed extensively in modem medical 
practise. The standardisation of procedures and advanced technology used, 
require integrated supervision from medical and technical staff. The use of 
International guidelines ensures patient safety (Ross 2003). An exercise 
electrocardiogram is one of the first investigations carried out when screening for 
ischaemic heart disease.
Cardiopulmonary exercise tests are used in the assessment of a range of subjects 
from athletes to cardiac patients (the method is explained in chapter 2.18). 
Programmes can be designed to enhance a specific function, for example the 
ability to perform at exercise levels exceeding the individual’s anaerobic 
threshold. Thus, an improved tolerance to severe exertion can be developed. 
Similarly the quantitative nature of results horn exercise tests can be used to 
classify the severity of disability occurring due to a pathological condition such 
as chronic heart failure. Data from exercise tests can also be used to provide 
prognostic information and serial testing can objectively evaluate the success of 
therapeutic interventions (Bocchi et al. 1995). In the case of patients with cardiac 
failure, cardiopulmonary exercise testing forms part of the selection process for 
cardiac transplantation referral (Ross 2003).
1.7 Detrimental clinical effects of right ventricular apical 
pacing
As early as 1925, Wiggers et al demonstrated that epicardial RVA pacing in 
open-chested dogs was associated with a diminished rate of change in left 
ventricular pressure (dP/dt) and dyssynchronous left ventricular contraction
34
pattern. It was postulated that this resulted from slower transmyocardial 
conduction compared to the normal rapid conduction mediated by the His- 
Purkinjie system. Another study confirmed that pacing induced cardiac 
dyssynchrony as assessed by radionuclide angiography resulting in deterioration 
in cardiac performance (Boucher et al. 1983). Further support for the detrimental 
effects of artificial pacing was seen in 1986 (Adomian & Beazell 1986) , when 
investigators produced complete heart block in 12 dogs and paced them 
electrically at the RVA for 3 months. Myofibrillar disarray was observed in 9 
(75%) of these dogs.
In the 1980s, the detrimental haemodynamic consequences of RVA pacing led to 
the introduction of dual chamber sequential pacing to maintain atrioventricular 
synchrony (Boucher et al. 1983). However, despite this, subsequent studies 
provided further evidence that RVA pacing continued to result in 
dyssynchronous left ventricular activation, and therefore impaired 
haemodynamic function (Little et al. 1982; Park, Little, & O’Rourke 1985).
In 1997, a key paper was published by Anderson et al (Andersen et al. 1997) in 
which they randomised 225 patients with sick-sinus syndrome to either single­
chamber atrial pacing (11=110) or single-chamber ventricular pacing (n=115). 
They found that after a mean follow-up of 3.3 years, atrial pacing was associated 
with significantly less atrial fibrillation and thromboembolism whereas there was 
no significant difference in mortality and heart failure between the two groups. 
The detrimental effects induced by ventricular pacing were maintained when the 
patients were examined 8 years later. They recommended that patients with sick-
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sinus syndrome should be treated with an atrial rather than ventricular pacing 
system for the above mentioned benefits and to avoid the unfavourable 
symptoms of atrioventricular desynchronisation in the form of pacemaker 
syndrome. In 2001, Tantengco et al (Tantengco, Thomas, & Karpawich 2001) 
assessed the long-term global LV function in 24 patients who were paced from 
the RVA at a young age. The mean follow-up was 9.5 years. They demonstrated 
impaired systolic and diastolic LY function in the paced group when compared to 
the control group. They recommended exploring alternative pacing sites that 
aimed to provide normal biventricular activation, especially in paediatric patients 
requiring long-term pacing.
In 2002, the Dual-Chamber and VVI Implantable Defibrillator (DAVID) trial 
(Wilkoff et al. 2002) was conducted on 506 patients with an indication for an 
implantable cardioverter defibrillator (ICD) without any indication for 
ventricular pacing. Patients were randomised to either ventricular backup pacing 
at 40/min (VVI-40; n=256) or dual-chamber pacing with a relatively short 
atrioventricular (AV) interval (DDDR-70; n=250). The combined end point was 
death or hospitalisation for heart failure. The DAVID investigators demonstrated 
that in patients with LVEF < 40%, the dual-chamber pacing offered no clinical 
advantage over ventricular backup pacing. Sharma et al revisited the DAVID 
trial in 2005 to determine whether right ventricular pacing is an independent 
predictor of the composite outcome (Sharma et al. 2005). They found that the 
best separation for predicting endpoints occurred with DDDR RV pacing > 40% 
vs DDDR RV pacing < 40% (P = .025). Patients with DDDR RV pacing < 40% 
had similar or better outcomes to the VVI backup group (P = .07). Correction for 
baseline variables predictive of the composite outcome in the (nonpaced) VVI
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group (use of nitrates, increased heart rate, and increased age) did not change the 
findings for RV pacing (P = .008). In contrast, atrial pacing was not predictive of 
worse outcomes. They concluded that these results suggest, but do not prove, a 
causal relationship between frequent RV pacing and adverse outcomes in patients 
with left ventricular ejection fraction <40%.
Sweeney et al, in 2003, published the Mode Selection Trial (MOST) (Sweeney et 
al. 2003). This is a 6-year, randomised trial of DDDR versus VVIR pacing in 
SND. Cumulative percent ventricular paced (Cum%VP) was determined from 
stored pacemaker data. Baseline QRSd <120 ms was observed in 1339 patients 
(707 DDDR, 632 VVIR). Cum%VP was greater in DDDR versus VVIR (90% 
versus 58%, P < 0.001). Cox models demonstrated that the time-dependent 
covariate Cum%VP was a strong predictor of HF hospitalisation in DDDR 
(hazard ratio [HR], 2.99 [95% Cl, 1.15 to 7.75] for Cum%VP > 40%) and VVIR 
(HR 2.56 [95% Cl, 1.48 to 4.43] for Cum%VP > 80%). The risk of AF increased 
linearly with Cum%VP from 0% to 85% in both groups (DDDR, HR 1.36 [95% 
Cl, 1.09, 1.69]; VVIR, HR 1.21 [95% Cl 1.02, 1.43], for each 25% increase in 
Cum%VP). Model results were unaffected by adjustment for known baseline 
predictors of HF hospitalisation and AF. They, therefore, concluded that 
ventricular desynchronisation imposed by ventricular pacing even when AV 
synchrony is preserved increases the risk of HF hospitalisation and AF in SND 
with normal baseline QRSd. Nielsen et al. (Nielsen et al. 2003), in the same year, 
published a randomised study of patients with SSS and normal AV conduction to 
AAIR, DDDR with a short AV delay, or DDDR with a long AV delay. The mean 
follow-up was 2.9 years. DDDR pacing with a short AV delay resulted in a 
reduced LV fractional shortening (LVFS). Interestingly, in 2003, Simantirakis et
37
al studied 16 patients with a chronic RVA pacing to assess the effects of 
restoration of normal ventricular activation (Simantirakis et ah 2003). They 
concluded that the restoration of normal conduction acutely enhanced the 
contractile function without affecting myocardial oxygen consumption.
In 2004, Thambo et al (Thambo et al. 2004) performed echocardiography and 
exercise tests in 23 patients with congenital complete heart block before DDD 
pacemaker implantation and after at least 5 years of RVA pacing. They 
demonstrated that RVA pacing induced LV dyssynchrony with deleterious 
remodelling, dilatation, and asymmetrical hypertrophy. There was also a 
reduction in the overall exercise capacity. In the same year’, Puggioni et al 
(Puggioni et al. 2004) published the OPSITE Study-Acute, in which they 
compared LV pacing with RVA pacing in 44 patients undergoing AV junction 
ablation for permanent atrial fibrillation (AF). This study was a randomised 
single blind crossover trial in which all patients had two leads. The authors 
performed intrapatient comparison of the QRS width and echocardiographic 
parameters of the two groups. They demonstrated that ejection fraction (EF) 
following rhythm regulation increased by 17.6% in the LV pacing group and by 
11.2% in the RV pacing group. The mitral regurgitation score decreased by 
16.7% and 0%; and the diastolic filling time increased by 15.6% and 12.7% 
respectively. When compared to RV pacing, LV pacing resulted in a 5.7% 
increase in EF and 16.7% decrease in the mitral regurgitation (MR) score, with 
4.8 % shorter QRS. They concluded that rhythm regulation achieved by AV 
junction ablation improved EF in both groups. However, LV pacing provided an 
additional modest but favourable haemodynamic effect. This effect seemed to be
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equal in patients with both depressed and preserved systolic functions and in 
those with or without native left bundle branch block (LBBB).
In 2005 Steinberg et al (Steinberg et al. 2005), assessed whether RVA pacing in 
the I CD arm of the Multicenter Automatic Defibrillator Implantation Trial 
(MADIT II) was associated with an unfavourable outcome. During a 20-month 
follow-up, patients (n = 369) having high cumulative right ventricular pacing 
(>50%), had a higher incidence of new or worsened heart failure (30% vs 17%, P 
= 0.002; hazard ratio 1.9) and heart failure or death (50% vs 20%, P = 0.004; 
hazard ratio 1.8) compared to patients (n = 198) with infrequent right ventricular 
pacing. In addition, patients in the high-frequency pacing group had significantly 
more episodes of ventricular tachycardia events requiring shock or 
antitachycardia pacing by the defibrillator than did patients in the low-frequency 
pacing group (hazard ratio 1.5, P=0.025).
A year later, Kindermann et al randomised 30 patients with an EF < 40% and a 
standard indication for permanent ventricular pacing to either RVA pacing or 
biventricular pacing (Kindermann et al. 2006). This was a crossover study and 
patients had 3 months in each pacing mode. They demonstrated significant 
superiority of biventricular pacing to conventional RVA pacing with regard to 
LV function, quality of life, and maximal as well as submaximal exercise 
capacity. In the same year Lieberman et al. assessed haemodynamic data on 33 
patients (17 patients with EF > 40% and 14 patients with EF < 40%) during atrial 
and dual chamber pacing from the RVA, RV free wall, RV septum, LV free wall,
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and biventricular (Lieberman et al. 2006). They concluded that RV pacing at one 
or more sites worsens LV function in patients with or without LV dysfunction.
The SAVE PACe trial was published in 2007 by Sweeney et al (Sweeney et al. 
2007), They randomly assigned 1056 patients with sick sinus syndrome and 
intact AV conduction to receive conventional dual chamber pacing or dual 
chamber minimal RV pacing. The mean follow-up was 1.7 year's. They 
demonstrated that dual chamber minimal RV pacing prevented ventricular 
desynchronisation and moderately reduced the risk of AF in patients with SSS.
As a result of the detrimental effects RVA pacing, the authors recommended that 
pacing at this site should be either minimised or an alternative RV pacing site 
considered. In patients with sinus node dysfunction, minimising RVA pacing 
may be attempted by programming an extended atrioventricular delay, 
atrioventricular search hysteresis, or minimum ventricular- pacing algorithms that 
search for and promote intrinsic atrioventricular- conduction. Programming 
strategies, however, are not relevant for patients with atrioventricular conduction 
disturbance or patients who have undergone atrioventricular node ablation and 
require permanent ventricular* pacing. Therefore, other RV sites must be 
evaluated in an attempt to avoid the potential detrimental effects of RVA pacing.
1.8 Selective site right ventricular pacing
The term selective site pacing (SSP) refers to pacing at targeted RV sites while 
alternate site pacing refers to pacing at sites other than RVA (Lieberman et al. 
2004). It reflects the fact that the site is selected by the implanter in expectation 
of a more physiological depolarisation pattern and better haemodynamic
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response (de Cock, Giudici, & Twisk 2003), with less detrimental remodelling 
(Harris & Gammage 2000), and reduced long term complications such as 
perfusion defects and heart failure (Karpawich et al. 1991). Right ventricular 
outflow tract (RYOT) is the most targeted non-RVA site. In order to clarify the 
RYOT, this site will be defined anatomically, fluoroscopically and 
electrocardiographically. This is essential in order to standardise procedures and 
permit the comparison of the different sites.
1.8.1 Anatomical definition
There was no agreed consensus on the anatomical definition of selective pacing 
sites until 1999 when Giudici and Karpawich (Giudici & Karpawich 1999) 
proposed the following:
• RV inlet septal pacing: above, on, or beneath the annulus of the 
septal/anterior tricuspid valve (TV) leaflets resulting in a relatively normal 
QRS morphology and axis.
• RV infundibular septal pacing: proximal to pulmonic valve distal to, or near 
the crista supraventricularis resulting in LBBB with a vertical axis.
• RV outflow septal pacing (was most commonly referred to as RYOT): near 
the septal/moderator band insertion at a mid-position on the RV septum 
resulting in LBBB with a vertical axis.
• RV apical septal pacing: proximal to septal moderator band continuity; this 
does not typically produce a vertical QRS axis.
Later, in 2004, Lieberman et al formally defined the RYOT borders. They stated 
that in the anteroposterior (AP) projection, the lower RYOT border is a line
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extending from the tricuspid valve (TV) apex to the border of the RV (Lieberman 
et al. 2004). The pulmonary valve is the upper RYOT border. They also, for 
simplicity, divided the RYOT into 4 quadrants, horizontally by a line midway 
between the pulmonary valve and the RYOT lower border, and vertically by a 
line that connects the pulmonary valve to the RYOT lower border (dividing the 
RYOT into four quadrants: high septal, low septal, high free wall, and low free 
wall).
Mond et al, in 2007, published a review in which RYOT anatomy, radiographic 
views, 12-lead ECG appearances, and a novel stylet shape for positioning the RV 
lead were discussed (Mond et al. 2007). They explained that the septal RYOT 
(figures 1.2 & 1.3) is a misnomer, as much of it abuts the proximal ascending 
aorta and thus the superior and maybe part of the inferior RVOT “septum” lies 
above the aortic valve. Therefore, using the strict anatomical definition of a 
septum as a structure that can be removed without exiting the heart, only part of 
the inferior portion of the RYOT septum can be considered as truly septal. They 
also explained that from an electrophysiologisf s perspective, the walls of the 
RYOT can be divided into four segments; septal, anterior, posterior, and free.
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Figure 1.2: Illustration of the RYOT highlighting the RV septal anatomy. The 
RYOT is bordered by the pulmonary valve above and the superior aspect of the 
tricuspid apparatus below (Mond et al. 2007)
Anterior
Posterior
Left Atrium Right Atrium
Figure 1.3: Schematic of a cross-section of the chest to demonstrate the 
relationship of the four areas of the RYOT to surrounding structures. Depending 
on the level of the RYOT, behind the septum lies either the left ventricle (LY) or 
ascending aorta (Ao). Adapted from (Mond et al. 2007).
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1.8.2 Fluoroscopic definition
Lieberman et al defined the RYOT lower border by extending a pacing catheter 
parallel to the RV inferior border from the TV apex to the lateral RV border in 
the AP or the right anterior oblique (RAO) views (figurel.4) (Lieberman et al. 
2004) . The upper RYOT border is determined by positioning a pacing catheter 
through the pulmonary valve (PV) (noted by the loss of R wave on the 
intracardiac electrogram). The actual RVOT-PY junction is then identified by the 
appearance of dominant R waves as the catheter is withdrawn into the RV. The 
RAO view helps in determining the upper and lower halves of the RYOT. 
However, to differentiate RYOT septum from free wall, the LAO (left anterior 
oblique) view is used.
Figure 1.4: RYOT upper and lower fluoroscopic borders as shown in the right 
anterior oblique view (RAO) during an electrophysiology study with two 
catheters defining these borders (Lieberman et al. 2004)
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Later in 2007, Mond et al described that for RYOT lead placement, four views 
can potentially be helpful:
1- The postero-anterior (PA) view is helpful for determining if the lead lies 
within the RYOT upper and lower borders (Figures 1.5 & 1.6). This view, 
however, gives little help as to which RYOT segment the lead is actually 
attached to. RYOT free wall leads often point in an upward or superior direction, 
although this finding is not universal.
Figure 1.5: CXR in the PA position showing RV lead that appears to be fixed 
within the RYOT borders (black arrow points the lead tip)
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Figure 1.6: CXR in the PA position showing RV lead fixed to the septum below 
the RYOT borders (black arrow points the lead tip)
2- The 40° right anterior oblique (RAO) view helps confirm RYOT 
positioning (Figure 1.7). It is not unusual for a lead to enter the coronary sinus 
and lie within the great cardiac vein. The RAO confirms the posterior aspect of 
the lead in the cardiac venous system. The same principle can be applied to RY 
apical pacing and inadvertent positioning of the lead in the middle or lateral 
cardiac vein. This view does not tell us to which part of the RYOT the lead is 
attached.
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Figure 1.7: Right Anterior Oblique (RAO) view showing RV lead fixed within 
the RYOT borders in a patient who had a previous coronary bypass operation 
with aortic valve replacement
3- The 40° left anterior oblique (LAO) view is best view to define the septal 
and free wall aspects of the RYOT. The septal position is characterised by a 
posterior orientation of the lead tip, which faces toward the right (Figure 1.8) and 
the free wall site by a leftward anterior orientation.
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Figure 1.8: Left Anterior Oblique (LAO) view for the same patient in figure 1.9 
confirming lead attachment to the RYOT septum.
4- The 90° left lateral (LL) view is also very helpful, but difficult to achieve 
during an implant using single plane fluoroscopy, because of sterile drapes, lead 
shields, arm boards, and monitoring equipment. A posterior projection of the lead 
tip indicates septal placement and is 100% specific (McGavigan et al. 2006). In 
comparison, a lead on the free wall passes anteriorly toward the sternum (Figures 
1.9, 1.10, and 1.11).
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Figure 1.9: Lateral CXR confirming RV lead attachment to the RYOT septum 
(black arrow points the lead tip)
Figure 1.10: Lateral CXR with RV lead attached to the RYOT free wall (black 
arrow points the lead tip)
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Figure 1.11: Lateral CXR with RV lead attached to the RYOT anterior wall 
(black arrow points the ventricular lead tip while the white arrow points to the 
atrial lead tip)
1.8.3 Electrocardiographical definition
Lieberman et al described the electrocardiographic Findings in lead I and AVF in 
relation to where the RYOT quadrant was paced (Table 1.1) (Lieberman et al. 
2004).
Table 1.1
Lead 1 Lead AVF
High septal (infundibular) - +
Low septal (outflow) - -/+
High free wall (infundibular) + +
Low free wall (outflow) + -/+
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Mond et al also demonstrated correlation between the 12-lead ECG and lead 
position (Mond et al. 2007). The septal RYOT is a more posterior and leftward 
structure than the free wall and this is reflected in the typical ECG patterns of 
pacing at these sites. Septal pacing produces a shorter QRS duration (McGavigan 
et al. 2006; Mera et al. 1999; Stambler et al. 2003; Tse et al. 2002) and typically 
a negative or isoelectric vector in lead I (Figure 1.12). This feature has a 90% 
positive predictive value for septal placement. Conversely, free wall sites are 
associated with prolonged QRS duration, notching of the inferior leads 
(particularly lead III), and a positive vector in lead I (McGavigan et al. 2006). 
Pacing at the anterior wall provides variation between these two appearances and 
frequently has an almost isoelectric vector in lead I.
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Figure 1.12: Typical ECG appearances of pacing from the RYOT free wall and 
septum. Lead 1 has been enlarged to show the differences between these sites 
with a QS wave for septal pacing and an R wave for the free wall. Notching of 
the QRS in lead III (enlarged) is often seen with free wall pacing. A fusion beat 
(F) is noted on the first tracing (Mond et al. 2007).
Hillock et al (Hillock, Stevenson, & Mond 2007), illustrated a helpful method to 
shape the stylet by which the ventricular lead can be reproducibly positioned to 
the RYOT septum. This can be achieved by initially creating a generous primary 
curve with the terminal 2 cm of the wire bent to form a secondary curve creating 
a swan neck deformity. Finally, and to be able to reliably point the lead tip 
towards the septum, the secondary curve is modified to make the last 2 cm point
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posteriorly (Figures 1.13 & 1.14). They demonstrated that septal RYOT pacing 
results in a narrower QRS duration, compared to anterior or free wall pacing (136 
vs 155 ms, P < 0.001). Alternatively, leads can be delivered to the RYOT using 
steerable or shaped catheters.
Figure 1.13: The prepared stylet with a generous primary curve and a terminal 2 
cm bend to form a secondary curve creating a swan neck deformity. The 
secondary curve is then modified to make the last 2 cm point posteriorly.
angulation
Figure 1.14: Schematic illustration of the stylet appearance in different 
fluoroscopic projections.
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1.9 Trials on selective site pacing
Due to the potential detrimental effects of RVA pacing, SSP has been evaluated. 
Selective site pacing trials in humans were discussed in the 1980s, but the 
technical application only occurred in the early 1990s. This delay was due to the 
fact that long-term studies of SSP on humans have been hindered by many 
factors (Gammage & Marsh 2004). Firstly, there was a lack of uniform 
definitions for selective pacing sites; this may also have contributed to the 
conflicting results of published data. Secondly and until relatively recent times, 
there was an inability to place leads at specific sites with adequate stability and 
reproducibility (passive fixation leads were designed to be placed in the RVA). 
Thirdly, the mechanical and electrical performance of most pacing leads remains 
uncertain if placed in non-traditional sites. Thus, valid randomised controlled 
trials (RCT) have been difficult to design and conduct. In addition, the 
introduction of cardiac resynchronisation therapy (CRT) led to some confusion 
with regard to the role of, and patient selection for, SSP. Unlike CRT, SSP is 
largely designed to optimise LV function by minimising or abolishing RVA 
pacing induced detrimental effects. Selective site pacing is not an alternative or 
competitor for CRT; this confusion has lead to misleading conclusions from a 
number of studies with the result that consideration of SSP has been hindered 
(Brady & Hammill 2003; Stambler et al. 2003). There is a growing consensus of 
agreement that patients with a pacemaker indication with a prospectively high- 
degree of ventricular stimulation, reduced LV-function, with or without signs of 
heart failure, should receive a biventricular pacing device (Doshi et al. 2005). 
However, this is not evidence based and several large multicentre studies are 
currently underway to explore the best pacing option in patients with standard
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pacing indications and variable left ventricular function who do not meet the 
current criteria for CRT (e.g. BLOCK-HF study, PREVENT-HF study, 
BIOPACE study). Table 1.2 shows most previous trials conducted on SSP, 
presented in a chronological order (Table 1.2.A shows the observational trials 
while Table 1.2.B shows the prospective randomised trials).
Table 1.2.A: Observational Trials on Selective Site Pacing
Study Objectives N&Design F U Findings
Benchimol et
al, 1966
Compare haemodynamics with RV
outflow, RV midportion, and RV
inflow tract pacing
6
observational
acute No difference in the cardiac output, stroke volume, and
mean BP between sites.
Barold et al,
1969
Compare haemodynamics with RV
inflow and outflow tract pacing
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observational
acute Haemodynamic sequelae of pacing the RV outflow and
inflow' are similar.
Cowell et al,
1994
Compare septal and apical RV
pacing in patients with heart failure
15
observational
acute Apical VDD pacing did not increase the CO significantly,
whereas septal VDD pacing did.
Alboni et al,
1998
Compare acute haemodynamics
during ODD pacing with different
RV lead position (RVA, RVS, and
RVOT)
21
observational
acute No difference in cardiac function when pacing from RVA,
RVS, or RVOT
Deshniunkh
et al, 2004
Compare Direct His Bundle Pacing
(DHBP) with RVA pacing in
patients with cardiomyopathy (EF
23%-i:l 1%), persistent AF, & normal
QRS
39
non-
randomised
mean FU 42
months
DHBP is safe, effective and increases EF, cardiopulmonary
reserve and improves NYHA class when compared to
RVA pacing.
Stephen
Vlay, 2006
Examine technical, procedural, and
stability of RVOT-P
460
retrospective
9 yrs
experience
84% implantation success over the 9-yrs period. No
significant difference in pacing threshold, sensing, or
impedance between RVA pacing and RVOT-P.
Vanerio et al,
2008
Compare all-cause mortality in RVA
pacing (95 pts)and RVOT-P (55pts)
in pts > 70% paced
150
retrospective
5 yrs 32% died in the RVOT group with 51% in the RVA group
(P=0.02), RVOT-P appears to improve medium and long­
term survival
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Medi & To assess long-term RVOT lead 100 1 year long-term RVOT lead performance is satisfactory and
Mond 2009 performance retrospective comparable to traditional pacing sites.
Table 1.2. B: Prospective Randomised Trials on Selective Site Pacing
Study Objectives 1 N&Design FU Findings
Brian et al. Compare RVA pacing with RVOT pacing 33 73 long-term electrical performance and complications
1991 randomised months were comparable the in both groups.
Giudici et al. Compare RVA with RVOT pacing 89 acute 18.8% improvement in CO by velocity time integral
1997 randomised in RVOT-P compared with RVA pacing
Buckingham Compare pacing either RVA, or RVOT or both 11 acute Trend for better CO in the RVOT or both sites
et al, 1997 randomised pacing. QRS was significantly narrower in the dual
site pacing.
Karpawick Evaluated LV function after pacing RA, RVA, 22 acute LV function is maintained by septal and deteriorates
and Mital, and RV septum in young patients with normal randomised with RVA pacing.
1997 cardiac anatomy
Buckingham Examine the acute effects of RVOT, RVA, 14 acute No statistically significant differences between
et al, 1998 and dual site pacing in patients with low EF randomised pacing sites. Trend towards better parameters in
(mean EF 32%) RVOT and dual site pacing.
de Cock et Compared cardiac index in RVA and RVOT 17 acute Mean cardiac index was greater with RVOT pacing
al, 1998 pacing randomised at all heart rates (85,100 and 120).
Mera et al, Compare ventricular function during high RV 12 2 Septal pacing resulted in a narrower QRS, greater
1999 septal and apical pacing after His-bundle randomised months fractional shortening, and a greater resting (but not
ablation for refractory atrial fibrillation cross-over exercise related) EF.
Victor et al, Compare RVOT with RVA pacing in patients 16 4 No significant differences were found in NYHA
1999 with chronic atrial tachyarrhythmia and prospective months class, EF, exercise time, and PV02. The results were
complete AV block randomised then 3 identical whether EF < 40% or > 40%
crossover months
Schvvaab et Investigate the correlation between LV 14 acute Shorter QRS with alternate site. This correlated with
al, 1999 function and QRS duration obtained by randomised homogenisation of LV contraction and improvement
alternate RV pacing sites in systolic function but the differences in EF were
minor (mostly a change of < 10%).
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Kolettis et at
2000
Compare LV haemodynamics during short­
term AV sequential pacing from RVA and
RVOT in normal hearts.
20
randomised
acute
(5 min)
Pacing of both sites dropped BP with no significant
difference between sites. CO was also unchanged
between sites, but maximum negative dP/dt
decreased significantly with RVA only.
Tse et al. Compare RVOT with RVA pacing in Pts with 24 18 No difference at 6 months, but at 18 months: RVOT
2002 CHB randomised months patients had better EF, less perfusion defects and
less RWMAs
Stambler et Compare RVOT & RVA pacing in patients 103 9 QoL-> no difference between RVA, RVOT, or dual
al/the with NYHA class II-III HF (EF<40%) & randomised, months site pacing. LVEF was higher at 9 months in RVA
ROVA chronic AF & bradycardic indication (VVIR) crossover pacing
study) 2003
Occhetta et Compare RVA pacing with para-Hisian pacing 16 2 six- No significant improvement in NYHA class, QOL,
al, 2006 in patients with chronic AF and narrow QRS randomised month 6 MWT, MR, TR& interventricular
who underwent AVN ablation crossover periods electromechanical delay during tire para-Hisian
pacing.
Res et al, Evaluate bifocal pacing (RVA & RVOT) in 42 6 Bifocal pacing improved EF, NYHA, 6MWT, and
(the
BRIGHT
patients with indication for CRT (EF < 35%) randomised
crossover
months MLWHF score when compared to VVI back up
pacing (40bpm).
study) 2007
Cate et al, To assess whether echocardiography can aid in 14 acute RVOT and apical pacing comparably worsen the
2008 selecting the optimum pacing site randomised 5-min echocardiographic normal LV
For better understanding and classification of these trials, the main findings will 
be presented in an attempt to answer the following 3 questions:
1- Is SSP feasible and safe?
2- Does SSP provide better acute LV haemodynamics compared to RYA pacing?
3- Does SSP provide better intermediate and long-term LV haemodynamics 
compared to RVA pacing?
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1- Is selective site pacing feasible and safe?
The first randomised trial on SSP was conducted in 1991 by Barin et al. They 
randomised 33 consecutive patients requiring ventricular pacing to either RVA 
pacing or RYOT pacing. The mean follow up was 73 months. This study showed 
that long-term electrical performance and complications were comparable in both 
groups; this paved the way for future clinical studies using non-apical RV sites 
(Barin etal. 1991).
A larger study evaluating 460 consecutive RYOT implants was published in 
2006 by Stephen Vlay who reported an overall 84% implantation success over a 
9-year period (Vlay 2006). The success rate was higher at 92% in the second half 
of the study period. In a subgroup comparison, at 20 months, of RVA and RYOT 
pacing, there were no significant differences in pacing threshold, R-wave 
sensing, or pacing lead impedance. Lead dislodgment occurred in only 1 of 460 
patients. Reasons for failure to implant in the RYOT included: inability to find a 
stable position with adequate pacing and sensing thresholds (related to anatomy, 
scarred myocardium, pulmonary hypertension, and tricuspid regurgitation), 
haemodynamic instability limiting time for implant, and a learning curve. Long­
term stability and lead performance were excellent. Medi and Mond (Medi & 
Mond 2009) retrospectively studied a total of 100 patients with ventricular lead 
placement on the RYOT septum undergoing pacemaker implantation for 
bradycardia indications. They confirmed lead positioning with the use of 
fluoroscopy. Long-term (1 year) follow-up was obtained in 92 patients. This 
study confirmed satisfactory long-term performance with leads placed on the 
RYOT septum, comparable to traditional pacing sites. In summary, RYOT
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placed leads perform as well as RVA placed leads in the short, intermediate, and 
long-term.
2- Does selective site pacing provide better acute left ventricular 
haemodynamics compared to right ventricular apical pacing?
Trials assessing acute haemodynamics with SSP have provided conflicting 
results. Several trials showed no difference (or statistically insignificant 
difference) in acute cardiac haemodynamic variables (CO, EF) between RVA 
pacing and RYOT pacing (Barold et al. 1969; Benchimol & Liggett 1966; 
Buckingham et al. 1998; Lieberman et al. 2006; Padeletti et al. 2007; ten Cate et 
al. 2008) Meanwhile a few randomised trials suggested better acute LV 
haemodynamics with RYOT pacing (Buckingham et al. 1997; de Cock et al. 
1998; Giudici et al. 1997; Karpawich & Mital 1997). However, it should be 
stressed that the results of these trials have been obtained in different clinical 
settings, using variable endpoints obtained with different techniques. It should 
also be emphasised that LV haemodynamics are affected differently when 
biventricular pacing is used for a heart failure indication compared to pacing to 
prevent the consequences of bradyarrhythmias. Due to this inconsistency of the 
clinical studies and the non-standardised definition of the SSP site, it is still 
unclear whether SSP provides better acute LV haemodynamics when compared 
to RVA pacing. It is possible that positive or negative remodelling in LV 
function can be a prolonged process and thus cannot be detected in the acute 
phase.
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3- Does selective site pacing provide better intermediate and long-term 
functional status and left ventricular haemodynamics compared to right 
ventricular apical pacing?
The assessment of intermediate and long-term LY haemodynamics in SSP has 
faced many challenges. Firstly, long-term follow up has proved difficult due to 
the fact that the majority of these patients are elderly with different indications 
for pacing and multiple comorbidities. Secondly, there is the inherent anatomic 
heterogeneity in the SSP site. Additionally, studies on intermediate and long­
term LV haemodynamics have utilised differing methodologies (prospective/ 
retrospective; crossover or parallel groups). The outcome measures have also 
differed with some “soft endpoints” utilised and possible investigator influence 
due to lack of blinding procedures. Consequently, these studies have produced 
conflicting results once more and have been subject to much criticism. The 
methodology and outcomes of the more robust trials will be reviewed in detail.
In the study by Victor et al, investigators compared the haemodynamic effects of 
RYOT pacing with RVA pacing in 16 patients with chronic atrial 
tachyarrhythmia and complete AY block over a 7 month period in a randomised 
crossover fashion. LVEF was > 40% in 10 patients and < 40% in 6 patients 
(Victor et al. 1999). A DDDR pacemaker was connected to 2 ventricular leads. 
The RYA lead was connected to the ventricular port whist the RYOT lead was 
connected to the atrial port. The pulse generator was programmed to either AAIR 
(hence RYOT pacing) or VVIR (hence RVA pacing) for 4 months before 
crossing over to the other pacing site for a further 3 months. No significant 
differences were found in New York Heart Association (NYHA) class, EF,
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exercise time, and maximal oxygen uptake. The results were identical in those 
patients with an EF < 40% and in those with an EF > 40%. The lack of positive 
results may reflect the small sample size, the relatively short period of follow-up 
or the inequity in the two periods of evaluation. It is also possible in this study 
that the presence of two ventricular leads has affected the right ventricular 
haemodynamics by inducing tricuspid regurgitation especially in those with a 
LVEF < 40%.
In 2003, the ROVA study (Stambler et al. 2003) investigators evaluated RVA, 
RYOT, and dual site pacing in 103 patients with NYHA class II-III heart failure 
(EF < 40%) and chronic AF with a conventional bradycardic pacing indication 
(VVIR pacemaker). This was a randomised crossover trial. The authors showed 
no difference in QOL or LVEF between RVA, RVOT, or dual site pacing at 3 
months. However, after 9 months, LVEF was higher (P=0.04) in those assigned 
to RVA rather than RVOT pacing. It would be interesting to conduct such a 
study for a longer duration to ascertain whether pacing-induced LV remodelling, 
and possibly QOL scores, take longer to be significantly detected. As this study 
included only patients with LVEF < 40%, it is quite possible that pacing will 
result in more deleterious haemodynamic effects in comparison to patients with 
normal or near normal systolic LV function.
The first positive study was published in 1999 by Mera et al. They studied 12 
patients undergoing His-bundle ablation for control of ventricular rate in chronic 
atrial fibrillation (Mera et al. 1999). A DDDR generator was implanted with the 
RVA lead comiected to the ventricular port and the RV septum lead to the atrial
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port. This enabled a randomised crossover design, with pacing for 2 months at 
each site commencing immediately after successful ablation and implantation of 
the device. Septal leads were positioned using electrocai'diographic (ECG) 
criteria and patients were paced with a lower rate of 80 beats per min. Septal 
pacing resulted in a significantly narrower QRS, greater fractional shortening, 
(0.31 ± 0,05 vs. 0.26 ± 0.07, P < 0.05) and a greater resting (but not exercise 
related) EF (0.51 ± 0.14 vs. 0.43 ± 0.10, P < 0.05). Chronic pacing parameters 
were similar at both sites.
The second positive study was published in 2002 (Tse et al. 2002). Investigators 
studied the effect of pacing site on myocardial perfusion and LV function by 
randomising 24 patients with complete AV block to receive RVA or RVOT 
leads. There was no difference between the two groups at 6 months, but at 18 
months, RVOT patients had a higher EF, less perfusion defects and regional wall 
motion abnormalities (RWMA). They concluded that RVOT pacing prevented 
the long-term deleterious effects of RVA pacing.
A further important study was published in 2007 by Res eta al [The BRIGHT 
study, (Res et al. 2007)]. Bifocal pacing (combined RVA and RVOT pacing) was 
evaluated in 42 patients with NYHA III-IV, EF < 35%, QRS > 120msec, and 
LBBB. This was a crossover study in which patients were randomised to receive 
either bifocal pacing or the control mode (VVI back-up pacing at 40 bpm), each 
for a period of 3 months. Patients with bifocal RV pacing showed significant 
improvement in EF, NYHA, 6MWT and MLWHF score.
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All-cause mortality was only studied retrospectively by Vanerio et al in 2008 
(Vanerio et al. 2008), They studied 150 consecutive patients who underwent 
pacemaker implantation for complete AY block (spontaneous or after AV node 
ablation), symptomatic second-degree AV block, and symptomatic atrial 
fibrillation with slow ventricular response. During follow-up, 18 patients (32%) 
died in the RYOT group and 49 (51%) in the RVA group (log-rank p=0.02). Cox 
regression multivariate analysis showed that only 2 variables correlated with 
survival; outflow tract pacing had a negative correlation with P = 0.006 and 
LVEF < 40% showed a positive correlation with P = 0.003. They concluded that 
RVOT-P appeal’s to improve medium/ long-term survival and recommended 
conducting prospective randomised trials with a greater number of patients to 
confirm these findings.
All these studies were conducted on a small number of patients with relatively 
short follow up periods. LY remodelling is a prolonged process and further work 
is clearly indicated with longer follow-up and prospective evaluation of 
mortality.
1.9.1 Ongoing trials on selective site pacing
Ongoing trials were recently reviewed by Kaye et al (Kaye, Stambler, & Yee 
2009). They assessed 3 randomised prospective multicenter clinical trials that are 
still in progress. These studies compare the long-term effects of RY apical versus 
septal pacing on left ventricular (LV) function. The three trials are the Optimize 
RV Selective Site Pacing Clinical Trial (Optimize RV), the Right Ventricular 
Apical and High Septal Pacing to Preserve Left Ventricular Function (Protect
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Pace), and the Right Ventricular Apical versus Septal Pacing (RASP). Whist 
each study differed slightly in design and study population, combined, they 
would follow approximately 800 patients requiring frequent or continuous 
ventricular pacing for up to 3 years using the single primary end point of LVEF. 
Unfortunately, the Optimize RV trial was terminated early due to limited 
resources. The Protect Pace trial has finished recruiting and is yet unpublished. 
Finally, the RASP trial is struggling to recruit the required number of patients.
1.9.2 His and para-Hisian pacing
In theory, and in patients without bundle branch block, ventricular lead 
implantation at the His bundle would be ideal. By using the His-Purkinje 
conduction system, biventricular depolarisation would be physiologic and result 
in simultaneous contraction of both ventricles. Therefore this potential pacing 
site warrants specific separate discussion.
Deshmukh et al reported the first results of chronic direct His bundle pacing 
(DHBP) in 18 patients (Deshmukh et al. 2000). Although they were able to pace 
the heart with a paced QRS almost identical to the intrinsic activation, the study 
demonstrated clear challenges to His-bundle pacing. Lead implantation required 
electrophysiological mapping and was successful in 12 out of 18 patients only 
with a mean procedure time of almost 4 hours. The mean pacing threshold was as 
high as 2.4 V at 0.5 msec. Exit block or lead dislodgment occurred in 2 of the 12 
patients. Finally, sensed R waves were below 1.5 mV in 8 of these 12 patients. In 
another study, by the same group, direct His bundle pacing was compared with 
RVA pacing in 54 patients with cardiomyopathy (EF 23% ± 11%), persistent AF,
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and normal QRS (Deshmukh & Romanyshyn 2004). Direct His bundle pacing 
was successful in 39 patients (72%). Twelve patients who received an RVA lead 
also underwent cardiopulmonary testing. After a mean follow-up of 42 months, 
29 patients were alive with a mean EF improving from 23% to 33% and NYHA 
functional class improving from 3.5 to 2.2. Cardiopulmonary exercise testing 
revealed longer exercise time in direct His bundle pacing compared to RVA 
pacing (280 ± 104s vs. 255 ± 110s), higher 02 uptake (16 ± 4 ml/kg/min vs. 15 ± 
4 ml/kg/min), and later anaerobic threshold (145 ± 74s vs. 126 ± 71s). They 
concluded that direct His bundle pacing was safe, effective and increased 
cardiopulmonary reserve when compared to RVA pacing.
In 2006, Zanon et al reported a higher success rate of 92% (24 out of 26 patients) 
when a steerable catheter was used with a mean procedure time of 75 min (Zanon 
et al. 2006). More recently, the same group studied myocardial perfusion using 
Tc99m-SestaMIBI in 12 patients with one lead positioned in the RVA and 
another in the His bundle (Zanon et al. 2008). Direct His bundle pacing was 
superior to RVA pacing in preserving the physiologic distribution of myocardial 
blood flow and reducing mitral regurgitation and LV dyssynchrony (as assessed 
on echocardiography and tissue Doppler imaging).
Another area of potential interest is the concept of Para-Hisian pacing which is 
defined as pacing with an intrinsic QRS different from the paced one in either 
morphology or duration, and widening of the QRS with voltage reduction due to 
loss of His bundle capture. Para-PIisian pacing was compared with RVA pacing 
in 16 patients with chronic AF and narrow QRS who had undergone AVN
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ablation (Occhetta et al. 2006). Occhetta et al implanted a dual-chamber 
pacemaker connected to a screw-in lead positioned in close proximity to the His 
bundle and another lead in the RVA. After two randomised six-month periods 
(with para-Hisian and RVA pacing), there was a significant improvement in 
NYHA functional class, QOL, 6 minute walk test, mitral regurgitation, tricuspid 
regurgitation and interventricular electromechanical delay during para-Hisian 
pacing.
In conclusion, recent improvements in lead technology and delivery systems 
make direct His bundle pacing and para-Hisian pacing feasible. However, this 
requires EP mapping, takes longer, carries a higher risk of sensing or pacing 
failure, and a higher lead dislodgment rate. Hence, all studies to date used a 
second “back up” RVA lead.
1.10 Study rationale and objectives
The long-term harmful effects of RVA pacing have been well described and 
accepted. It is clear that selective site ventricular pacing is rapidly evolving. 
However, most studies on SSP have been relatively small, with variable design 
and different end points. They have therefore provided conflicting results. There 
is a paucity of long-term data from carefully designed studies. Of particular 
concern is the fact that patients with impaired LVEF are at even greater risk from 
RVA pacing. The large landmark trials, such as the DAVID study, recommend 
minimisation of RVA pacing by using atrial based pacing modes to maintain 
AVN conduction. However, in patients who require ventricular pacing, the 
results of SSP trials have been disappointing. The optimal RV pacing site which
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provides the best haemodynamic and clinical benefit is yet to be confirmed. This 
“optimal” pacing site could actually vary between patients and therefore may 
need to be individualised based on the pacing indication;, LVEF, or other 
unknown factors.
Assuming that RYOT pacing can preserve the LV haemodynamics and therefore 
produce better cardiac output, this should be reflected in a better functional 
performance in patients receiving RYOT rather than RYA leads. The overall 
functional performance can be objectively assessed by measuring the peak 
oxygen consumption on CPET. None of the previous studies comparing RYOT 
with RYA pacing, but one (Victor et al. 1999), included PVO2 as a study 
outcome. In this study by Victor et al only 16 patients with chronic atrial 
tachyarrhythmia and complete AY block were included.
Our study is a single-centre, single blinded, randomised prospective trial. We 
evaluated the effects of RYOT pacing on the haemodynamic and functional 
recovery of patients requiring permanent right ventricular pacing. The primary 
outcome was cardiopulmonary functional capacity as measured by peak oxygen 
consumption (PVO2). Secondary endpoints included: exercise time, NYHA heart 
failure functional class, MLWHF score, SF-36 score, QRS duration, left 
ventricular ejection fraction, left ventricular end-diastolic diameter, mitral 
regurgitation grade, and CARE-HF dyssynchrony criteria.
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CHAPTER TWO
Methods
2.1 Summary of the protocol
Title of Study A Study Evaluating the Effects of Selective Site Pacing 
on the Haemodynamic and Functional Recovery in 
Patients Requiring Permanent Right Ventricular Pacing
Planned Study Period March 2006 to January 2009
Study Design Single-centre (Liverpool Heart and Chest Hospital), 
randomised, prospective
Number of Subjects 50
Eligibility Patients requiring permanent right ventricular pacing:
1- Patients with atrial fibrillation or flutter 
requiring AV nodal ablation on symptomatic 
grounds.
2- Patients with chronic AVN disease requiring 
permanent pacing.
Objectives To investigate:
• Whether patients who require permanent right 
ventricular pacing derive haemodynamic and 
functional benefit from RYOT pacing compared to 
RVA pacing.
• The effect of RYOT and RVA pacing on quality of 
life, resting Echocardiographic parameters and sub 
maximal exercise.
Endpoints Primary endpoints
• Cardiopulmonary functional capacity as measured 
by peak VO2 (ml/kg/min)
Secondary endpoints
• Exercise time
• New York Heart Association Classification
• Systolic cardiac function determined by measuring 
ejection fraction (%)
• Left ventricular size as assessed by measurement of 
the left ventricular end diastolic diameter (mm)
• Quantitative assessment of mitral valve regurgitation
• Evidence of left ventricular dyssynchrony
Measurement of pulmonary and aortic ejection 
systolic delays, as well as inter and intra-ventricular 
mechanical delays
• QRS width (ms)
• Minnesota Living With Heart Failure scale 
(MLWHF)
• Short-form 36 quality of life index
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2.2 Hypothesis
We hypothesised that pacing at the right ventricular outflow tract compared with 
right ventricular apex achieves better cardiopulmonary exercise capacity and 
dynamic cardiac function in patients requiring constant right ventricular pacing.
2.3 Inclusion criteria
Patients were included in the study if they had the ability to provide informed 
consent and had either atrial fibrillation or flutter requiring AV nodal ablation, or 
chronic high-grade AVN block (Mobitz II or grade III AVN block).
2.4 Exclusion criteria
Patients were excluded from the study if they had one or more of the following:
i- Indication for implantable cardioverter defibrillator or biventricular 
pacemaker.
ii- Exercise limitation due to other pathological process e.g. angina, 
respiratory, neurological or rheumatological disease
iii- Significant valvular heart disease
iv- Current or recent participation in any other clinical investigation
v- Life expectancy less than 2 year's
vi- Percutaneous or surgical revascularisation within 3 months
vii- Patient inability to independently comprehend the patient information 
sheet or inability or unwillingness to provide informed consent
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2.5 Definition of study outcomes
2.5.1 Primary endpoint
Cardiopulmonary functional capacity was assessed using a cycle ergometer and a 
standard ramp protocol with one minute increments in 10 watt work load. The 
maximal value of oxygen utilisation per minute corrected for body mass, peak 
VO2 (ml/kg/min), was taken as the peak exercise value, provided the anaerobic 
threshold has been exceeded.
2.5.2 Secondary endpoints
i- Exercise time was measured in seconds from the onset of exercise to the point of 
termination.
ii- New York Heart Association Functional Capacity Class as revised by the Criteria
Committee of the American Heart Association in 1994 was applied.
Class I: Patients with cardiac disease but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnoea, or angina.
Class II: Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnoea, or angina.
Class III: Patients with cardiac disease resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnoea, or angina.
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Class IV: Patients with cardiac disease resulting in inability to cany on any physical 
activity without discomfort, Symptoms of heart failure or anginal syndrome may be 
present even at rest. If any physical activity is undertaken, discomfort is increased.
iii- Ventilatory equivalent for 02 at 1L/ V02 as defined: the minute ventilation at an 
oxygen consumption of 1 litre per minute.
iv- Left ventricular’ systolic function as determined by:
1- The ejection fraction (EF) measured by Simpson’s rule of discs
2- Left ventricular outflow tract velocity time index (VTI)
3- Left ventricular size as determined by the measurement of left ventricular'
end -diastolic diameter (LVEDD) in the parasternal long axis view using 
M-mode Echocardiography (after making sure it is perpendicular’ to the 
short axis parasternal view)
v- Left ventricular dyssynchrony as defined by 2 of the following 3 criteria:
1- Aortic pre-ejection delay >140 ms (atrioventricular)
2- Aortic pre-ejection delay minus pulmonary pre-ejection delay > 40ms 
(inter-ventricular)
3- Posterolateral latency (D1 > D2) (intra-ventricular)
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vi- QRS width determined by a standard 12-lead ECG (150 Hz, 25 mm/s, and 10 
mm/mV) measurement from the onset of the Q wave to the end of the S wave 
(Nishiyama et al. 1993) .
vii- Health-related quality of life indices using the Minnesota Living with Heart 
Failure scale and the Short-form-36. The Minnesota Living with Heart failure is a 
21-item self-administered questionnaire quantifying different clinically-relevant 
aspects of the heart failure status including: physical limitation, treatment 
satisfaction and disease perception/quality of life. The short-form SF-36 is a 
general survey of health status and an outcome measure in clinical practice, and 
can be used together with disease-specific instruments for patient evaluation. The 
survey was either self-administered or completed by an interviewer when the 
patient was incapable of filling the questionnaire due to visual impairment. This 
was performed by reading the form and recording patient’s answers.
2.6 Major adverse cardiac events
• Death
• Ventricular Fibrillation, requiring cardioversion
• Cardiac Arrest, requiring CPR
• Lead displacement
• Pneumothorax
• Haematoma, requiring evacuation
• Failure to capture of pacing lead
• Pericardial effusion
• Cardiac tamponade
• Hospitalisation for heart failure
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2.7 Recruitment
Study patients were recruited into the trial from the routine clinical waiting list, 
and from the hospital wards (Liveipool Heart and Chest Hospital) .Those 
consented for the trial were included in the trial register.
RVA pacing RVOT pacing
RANDOMISATION
Patient Entry into trial register
Written informed consent form
Admission for pacemaker Implantation
(Indus ion/ e xclusion)
6 months follow-up investigations 
CPET, quality of life questionnaire, ECG, and echocardiogram
Baseline investigations
CPET, quality of life questionnaire, ECG, and echocardiogram
- Patients with persistent atrial fibrillation or flutter 
requiring AV nodal ablation on symptomatic grounds
- Advanced AV block (CHB/ Mobitz II)
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2.8 Consent procedure
Patients from the routine waiting list for AV node ablation were pre-screened for 
inclusion/exclusion criteria and were informed about the trial by the 
investigators. Suitable in-patients with chronic high grade AVN block were also 
approached, providing they met the inclusion criteria and they were not requiring 
temporary pacing. Eligible patients were then approached for consent and given 
the patient information leaflet (see appendix 1). Consent included an explicit 
initial acceptance of the trial-related requirement for follow-up 
echocardiography, cardiopulmonary exercise tests and quality of life 
questionnaires. Patients had access to the information sheet approved by the local 
ethics committee (see appendix 2). Patients were free to ask questions to the 
investigators and were offered the opportunity to reflect on the issue or to seek 
advice from other sources such as family members or other health professionals 
involved in their care. Patients only entered the active phase having provided 
informed written consent. Patients who dropped out prior to randomisation and 
after registration, were logged onto the CONSORT diagram but were not 
included in the intention to treat analysis.
2.9 Pre-pacemaker implantation assessments
At baseline, prior to randomisation, all patients underwent standard routine 
clinical assessment. The collected data consisted of demographics, previous 
history, previous cardiac investigations, and current medication. Patients were 
required to complete the Minnesota Living with Heart Failure, SF36 quality of 
life questionnaires and assessment of heart failure status (see CRF in appendix 
3). An electrocardiogram, an echocardiogram and a cardiopulmonary exercise
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test were performed (methods of performing this will be detailed later in this 
chapter).
2.10 Randomisation
Patients were randomised in equal proportion into the two experimental groups 
(RVA versus RYOT pacing groups) using a local proprietary database. Block 
randomisation with random block sizes of 2, 4 and 6 was used to ensure 
numerical balance between the groups throughout the randomisation period. Key 
data were entered prior to randomisation, and then random allocations were 
generated. Once randomised, the patient was enrolled and data contributed to the 
primary outcomes.
2.11 Details of pacemaker implantation
All 50 patients had pacemaker implantation according to standard clinical 
practice. The pacemaker right ventricular lead was implanted at the RYA or 
RYOT positions according to the randomisation code as detailed below. A post­
implantation chest radiograph (CXR) was taken routinely in the postero-anterior 
and lateral positions. A pacemaker interrogation was also performed to make 
sure that the sensing and pacing threshold were satisfactory. The lower rate limit 
was programmed to 60 in all cases with the rate response on. Patients in need of 
AVN ablation had this performed at a subsequent hospital admission.
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Method 1 (right ventricular apical selective site pacing)
The RVA site was defined as the most inferior and lateral position providing 
acceptable pacing parameters (R wave of > 6 mV and a pacing threshold of < 1.0 
V) in the right anterior oblique view.
Method 2 (right ventricular outflow tract selective site pacing)
The RYOT site was defined as a position below the pulmonary valve and above a 
line drawn parallel to the RV inferior border, extending from the apex of the 
tricuspid valve (His) to the border of the RV in an antero-posterior view, with 
acceptable pacing parameters (as above). In cases of inability to achieve 
satisfactory pacing parameters, a different RVOT pacing site was chosen.
2.12 Baseline and follow-up investigations
All patients had an echocardiogram, cardiopulmonary exercise test and 
completed quality of life questionnaires at baseline (before randomisation and 
pacemaker implantation) and at 6 months post-pacemaker implantation. The 
investigators were not aware of the lead position at follow-up. The investigators 
accept that longer term follow up may yield further results but collection of such 
data was beyond the remit and resources of this thesis.
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Table 2.1: Investigations at baseline and follow-up
Measurement Baseline 6 months
QOL Questionnaires SF-36 and MLWHF SF-36 and MLWHF
ECG and QRS width, LVEF, LV size, QRS width, LVEF, LV size,
Echocardiography LVEDD, LV dyssynchrony. LVEDD, LV dyssynchrony,
mitral valve regurgitation mitral valve regurgitation
Cardiopulmonary Peak V02, ET, end-tidal PC 02, Peak V02, ET, end-tidal PC 02,
Exercise test VEfor02atlL/V02 VE for 02 at 1L/V02
Adverse events Death, VT, VF, lead Death, VT, VF, lead
monitoring displacement, pneumothorax, displacement, pneumothorax,
haemothorax haemothorax
2.13 Time and event schedule
Table 2.1: Time and event schedule
Event Screening Pre- Post- 6 months
Procedure Procedure follow-up
Screen log X
Informed consent signed X
Entry into trial register X
Inclusion/exclusion criteria met X
Physical Examination X
Medical History X
Randomisation X
Quality of life Questionnaire X X
Echocardiography X X
Cardiopulmonary Exercise test X X
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2.14 Trial coordination
The Clinical Trials Unit (CTU) at Liverpool Heart and Chest Hospital provided a 
central randomisation service, production of the final protocol, case record forms 
(CRFs), and a trial specific database (see appendix 3).
2.15 Ventricular lead positioning
2.15.1 Right ventricular apex
Entrance into the pulmonary artery on X-ray screening confirms that the lead has 
traversed the right ventricle and is neither in the atrium nor in the coronary sinus. 
The lead was then pulled back as the stylet is advanced. Once the lead tip falls 
toward the apex, the patient was asked to inspire deeply and the lead was 
advanced into place. This procedure is often accompanied by ventricular ectopy, 
the absence of which suggests that the lead is not in the ventricle. An alternative 
method used to gain entry to the ventricle was to form the stylet into a dogleg or 
a J shape and use it to direct the lead across the tricuspid valve. Once in the right 
ventricle, the shaped stylet was replaced with a straight one to facilitate 
positioning at the apex. The ideal fluoroscopic appearance of the right ventricular 
apical lead is one in which the lead’s tip is well to the left of the spine and is 
pointing anteriorly and slightly caudal (in the anteroposterior projection it may 
not be possible to distinguish whether a lead is in a posterior coronary vein, the 
left ventricle, or the right ventricular apex).
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2.15.2 Right ventricular outflow tract
As the RYOT is less trabeculated than the RVA, the use of an active-fixation 
lead is required. To place a lead in the outflow tract or septum, the lead was 
prolapsed into the pulmonary artery as described above. The lead is then 
withdrawn after inserting a curved stylet as described in Figure 1.15 and 
applying torque to drive the tip into the septum, so the lead tip can be fixed. If 
the pacing and sensing parameters were not satisfactory an alternative position 
were tried. All lead positions were confirmed by both left anterior oblique and 
right anterior oblique views in the laboratory.
2.16 Health related quality of life measures
Standardised health-related quality of life (HRQOL) measures are critical for a 
number of purposes. These include evaluating the progress in achieving health 
goals, assessing health disparities across different segments of the population, 
and measuring the effectiveness of health care interventions for age-related 
diseases. Below are brief descriptions of the two tools used in our study to assess 
the quality of life.
2.16.1 Minnesota Living with Heart Failure questionnaire
The Mimiesota Living with Heart Failure questionnaire was designed in 1984 to 
measure the effects of heart failure and treatments for heart failure on an 
individual’s quality of life. The content of the questionnaire was selected to be 
representative of the ways heart failure can affect the key physical, emotional,
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social and mental dimensions of quality of life without being too long to 
administer during clinical trials or practice. To measure the effects of heart 
failure symptoms, functional limitations and psychological distress on an 
individual’s quality of life, the MLHFQ asks each person to indicate using a 6- 
point (zero to five) Likert scale how much each of 21 facets prevents them from 
living as they desire.
The questionnaire assesses the impact of common physical symptoms - shortness 
of breath, fatigue, peripheral oedema, and difficulty sleeping - and psychological 
symptoms of anxiety and depression. In addition, the effects of heart failure on 
physical and social functioning are incorporated into the measure. Since 
treatments might have side effects in addition to ameliorating symptoms and 
functional limitations produced by heart failure, questions about side effects of 
medications, hospital stays and costs of care are also included to help measure 
the overall impact of a treatment on quality of life. Although the MLHFQ 
incorporates relevant aspects of the key dimensions of quality of life, the 
questionnaire was not designed to measure any particular dimension separately
2.16.2 The short form-36 health survey
The SF-36 was developed from work done by the RAND Corporation and the 
Medical Outcomes Study (MOS), based on the measurement strategy of the 
RAND Health Insurance Study in the 1980s. SF-36 is a multi-purpose, short- 
form health survey with only 36 questions. It yields an 8-scale profile of 
functional health and well-being scores as well as psychometrically-based 
physical and mental health summary measures and a preference-based health
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utility index. The SF-36 covers the following quality of life aspects: Physical 
Function (PF), Role Limitation (RL), Bodily pain (BP); Social Function (SF), 
General Mental Health (GMH), Role Limitation due to Emotional Problem 
(RLEP), Vitality, Energy, or Fatigue (VEF), General Health Perception (GMH), 
and Health Compared to Last Year (HCLY). The SF-36 can be either self- 
administered or administered by a trained interviewer, either in person or by 
telephone. Over the years, the SF-36 has been used in surveys of general and 
specific populations, for comparing the relative burden of diseases across 
different sub-groups and in differentiating the health benefits produced by health 
care treatments.
2.17 Echocardiogram
All echocardiogram studies were performed by one operator who is accredited by 
the British Society of Echocardiography (BSE) to minimise the inter-observer 
variability. If in doubt, it was discussed with a second accredited operator until 
agreement reached.
2.17.1 Left ventricular size measurement
This was measured using M-mode at mid ventricular level. This was achieved by 
optimising the parasternal long axis view with the septum and the posterior wall 
lying parallel. The M-mode cursor was then placed through opposing walls so 
that it intersects both at right angles. The left ventricular end diastolic diameter 
(LVEDD) was then measured Rom endocardium to endocardium edge at the end 
of diastole (Figure 2.1).
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2.17.2 Assessment of left ventricular global systolic function
This was assessed using Simpson’s method. This method is based on the 
principle of slicing the left ventricular cavity from apex down to the mitral valve 
annulus into a series of discs. The volume of each disc is then calculated 
automatically and disc volumes are added together to provide the total left 
ventricular volume. This was performed in two perpendicular planes (2-chamber 
and 4-chamber views) in both systole and end-diastole. This method was only 
used when a clear visualisation of the endocardium was possible in both 2- 
chamber and 4-chamber views.
2.17.3 Velocity time integral
This was calculated by obtaining a 5-chamber view and positioning the pulsed 
wave Doppler sample in the left ventricular outflow tract (LYOT). The LYOT 
spectrum is then traced and the area automatically calculated.
83
2.17.4 Dyssynchrony Assessment
Echocardiography has been extensively used to assess mechanical LY 
dyssynchrony. Many simple and complex methods were utilised in the field of 
cardiac resynchronisation therapy in an attempt to improve patient selection. In a 
prospective, multicenter setting, the Predictors of Response to CRT 
(PROSPECT) study tested the performance of these parameters to predict CRT 
response. It was concluded that there is no single echocardiographic measure of 
dyssynchrony that may be recommended to improve patient selection for CRT 
beyond current guidelines (Chung et al. 2008). In our study, we adopted simple 
reproducible criteria to assess LV dyssynchrony (Cleland et al. 2006) accepting 
that the pacing indication in our patients is different compared to patients 
undergoing CRT and that these LV dyssynchrony criteria were in fact validated 
and tested only in CRT candidates.
i- Aortic Pre-Ejection delay (APE)
This was measured in milliseconds (msec) and represents the distance between 
the start of the electrical depolarisation (beginning of QRS complex on the 
surface electrogram) and the start of the mechanical ejection at the level of the 
aortic valve (beginning of the VTI waveform on continuous wave Doppler, 
Figure 2.2). Three measurements were made and the mean was taken. In the 
CARE-HF trial (Cleland et al. 2006), this was considered abnormal if measured 
>140 msec.
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depolarisation (beginning of QRS) to the start of the mechanical ejection as
depicted by the dotted lines. In this case 3 measurements were made (104 msec)
ii- Pulmonary pre-ejection delay
This was measured in milliseconds (msec) and represents the distance between 
the start of the electrical depolarisation (beginning of QRS on the surface 
electrogram) and the start of the mechanical ejection at the level of pulmonary 
valve (beginning of the VTI waveform on continuous wave Doppler, Figure 2.3). 
Three measurements were made and the mean was taken. The interventricular 
delay was then calculated by deducting the PPE from the APE. In the CARE-HF 
trial, this was considered abnormal if measured > 40 msec.
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depolarisation (beginning of QRS) to the start of the mechanical ejection at the
level of the pulmonary valve. In this case 3 measurements were made (the mean
is 96 msec).
iii- Postero-lateral latency (intra-ventricular dyssynchrony, D1>D2)
D1 is measured in milliseconds (msec) and represents the distance between the 
start of the electrical contraction (beginning of QRS on the surface electrogram) 
to the peak excursion of the LV posterior wall (Figure 2.4). Three measurements 
were made and the mean was taken. D2 is measured from the beginning ot the 
QRS to the start of mitral valve opening in diastole (beginning of E wave on 
pulse wave Doppler, Figure 2.5). The LV is considered dyssynchronous if D1 > 
D2 (CARE-HF study).
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Figure 2.4: D1 measurement. The distance between the start of the electrical 
contraction (beginning of QRS) to the peak excursion of the LV posterior wall 
(mean value 410 msec).
Figure 2.5: D2 measurement. It is the distance between the start of the QRS to 
the beginning of E wave on pulse wave Doppler (mean value 523 msec).
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2.18 Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) provides assessment of the integrative 
exercise responses involving the pulmonary, cardiovascular, haematopoietic, 
neuropsychological, and skeletal muscle systems, which are not adequately 
reflected through the measurement of individual organ system function. This 
non-invasive, dynamic physiologic overview permits the evaluation of both 
submaximal and peak exercise responses, providing the physician with relevant 
information for clinical decision making. The use of CPET in patient 
management is increasing with the understanding that resting pulmonary and 
cardiac function testing cannot reliably predict exercise performance and 
functional capacity and that the overall health status correlates better with 
exercise tolerance rather than with resting measurements (Ross 2003).
CPET involves measurements of respiratory oxygen uptake (VO2), carbon 
dioxide production (VCO2), and ventilatory parameters during a symptom- 
limited exercise test. Peak exercise capacity is defined as the maximum ability of 
the cardiovascular system to deliver oxygen to exercising skeletal muscle and of 
the exercising muscle to extract oxygen from the blood. Consequently, exercise 
tolerance is determined by three factors: pulmonary gas exchange; cardiovascular 
performance, including the peripheral vascular tree; and skeletal muscle 
metabolism.
Several different methods exist for measuring ventilation and respiratory gas 
parameters during exercise. Most clinical systems rely on breath-by-breath 
analysis techniques because they provide the best measures of the metabolic
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response to exercise. A non-rebreathing valve is connected to a mouthpiece to 
prevent mixing of inspired and expired air (Figure 2.6 (Albouaini et al. 2007)). 
Oxygen and carbon dioxide gas analysers are usually incorporated in a 
"metabolic cart" designed specifically for functional testing. Respiratory volumes 
are computed by integrating the air flow signals over the time of inspiration and 
expiration. Average minute volumes are derived from the breath-by-breath data 
multiplied by the respiratory rate.
Figure 2.6: CPET machine using the Cycle ergometry. A non-rebreathing valve 
is connected to a mouthpiece with continuous ECG and blood pressure 
monitoring. Resuscitation equipments should be on hand (Albouaini et al. 2007).
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Many different protocols are used for functional testing (Table 2.3). The purpose 
of the test and the functional capabilities of the patient determine the choice of 
protocol. In evaluating patients with CHF, both bicycle and treadmill protocols 
have been used. We used the bicycle protocol in this study. The rate of workload 
progression is somewhat arbitrary, although it has been suggested that optimal 
exercise duration for functional assessment on the bicycle is between 8 and 17 
minutes (Buchfuhrer et al. 1983). Bicycle work is quantified in watts. The initial 
workload for patients with CHF patients is usually 20 to 25 watts and increased 
by 15 to 25 watts every two minutes until maximal exertion is reached. 
Alternatively, the workload can be computer controlled for electronically-braked 
bicycle ergometers, and a ramp protocol (e.g., 10 watts/min) is often used. The 
modified Naughton protocol is recommended for treadmill exercise testing in 
patients with heart failure (Naughton et al, 1963). This protocol is designed to 
increase the workload by approximately 1 MET (3.5 mL (Vkg/min) for each two 
minute stage. In our study, the cycle ergometry was used as it requires less 
muscle training, is safer in elderly patients and easier to conduct in patients with 
other comorbidities. Although it would have been ideal for the subjects to 
undergo a familiarisation session this was not feasible due to the time scale from 
patient presentation to pacing procedure.
Table 2.3: Exercise Equipment: Cycle Ergometry Vs Treadmill
Peak Oxygen content (PVO2) 
Work rate measurement 
Blood gas collection 
Noise and artefacts 
Safety
Weight bearing in obese
Cycle Treadmill
lower higher
yes no
easier more difficult
less more
safer less safe?
less more
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Degree of leg muscle training less more
More appropriate for patients active normal subjects
2.18.1 Oxygen uptake and peak Oxygen uptake
Oxygen uptake (VO2) is determined by cellular O2 demand up to some level that 
equates to maximal rate of O2 transport, which then is determined by that 
maximal rate of transport. As VO2 increases with increasing external work, one 
or more of the determinants of VO2 approach limitations (e.g., SV, HR, or tissue 
extraction) and VO2 versus work rate may begin to plateau. This plateau in VO2 
has traditionally been used as the best evidence of VO2 max.
The main determinants of a normal PVO2 are genetic factors, quantity of 
exercising muscle, age, sex, and body size. It can also be affected by training and 
patient motivation. PVO2 should be expressed in absolute values (litres per min) 
and as a percentage of the predicted value. VO2 can increase from a resting value 
of about 3.5 ml/kg/min (about 250 ml/min in an average individual) to PVO2 
values about 15 times the resting value (30-50 ml/kg/min). Athletes may attain 
values over 20 times their resting values (up to 80 ml/kg/min).
Figure 2.7 is an example of a normal CPET using Bruce protocol on a cycle 
ergometer. Table 2.2 shows the normal values of parameters derived from CPET. 
A typical example of CPET in HF patient is shown in Figure 2.8.
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Figure 2.7: CPET in a healthy man using Bruce protocol. The progressive linear increase in V02 is
noted, reaching a steady state after 2 min in each of the first two stages. PV02 was 3.09 litres /min.
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Figure 2.8: CPET in a 46 year old man with cardiomyopathy in NYHA class III. A modified
Bruce protocol was used. The patient reached a PVOi of 14 ml/kg/min (4 METs), 42% of
predicted for age, gender, and weight. VAT occurred at VOi of 955 ml/min (slopes intersection
point). This blunted cardiopulmonary response is typical in severe cardiomyopathy.
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Table 2.2 Normal CPET parameters
Variables Vormal Value
Peak oxygen content (PVO2) > 84% predicted
Ventilatory anaerobic threshold (VAT) > 40% PV02 (40-80%)
Maximum heart rate (HRmax) > 90% age predicted
Heart rate reserve (HRR) <15 Beats/min
Blood pressure (BP) < 220/90
02 Pulse (VO2/HR) >80%
Ventilatory Reserve (VR) MVV-VEmax >11L or VEmax /MW x 100 <85%
Respiratory rate (RR) < 60 breaths/min
Minute ventilation/ carbon dioxide <34
output ratio (VE/VCO2) at VAT
2.19 Power calculation and statistical analysis
Sample size calculations were focused on the primary end point assuming an 
absolute increment of 1.5ml/kg/min in peak V02 in the RYOT group compared 
to the RVA group. This was based on the studies by Victor et al and Kinderman 
et al (HOBIPACE) which demonstrated a mean peak V02 of 16.2 ml/kg/min in 
patients after RVA pacing. Allowing for a 5% non compliance or drop out rate 
the minimum number of patients required to detect a significant (p<0.05) 
difference between RVA and RVOT pacing with a power of 90% was 50.
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The primary statistical analyses were as per intention to treat. Secondary analyses 
were as per protocol basis (per treatment received). Data were expressed as 
percentages, mean value ± standard deviation (confidence interval), or as median 
(minimum, maximum). Continuous variables were compared using Student’s t- 
test assuming normal distributions or Wilcoxon rank sum test for variables with 
non-normal distributions. Dichotomous variables were compared via the % test 
and Fisher’s exact test. In all tests, P-values of 0.05 or less were considered 
significant.
Descriptive Statistics methodology was used on SPSS for Windows Version 
11.0.0 (Sep. 2001) and StatsDirect Version 2.7.2 (Sep. 2008). Initially, Baseline 
characteristics were explored to exclude significant differences between the RVA 
and RVOT arms, After FU, the following tests were performed for further 
analyses:
I- Wilcoxon Signed Ranks Test to compare baseline and FU variables in the 
whole study population (e.g. comparing baseline EF in the whole study 
population with the FU EF) and in each study arm.
II- Mann-Whitney Test to compare variables differences between RVA and 
RVOT groups (intention to treat analysis), e.g. compare the change 
(difference between baseline and FU) in EF in the RVA group with the 
change in the RVOT group. As per protocol analysis was also performed.
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CHAPTER THREE
Results
3.1 Overview
We screened 131 patients. A total of 60 failed to meet study criteria. A further 21 
declined participation (CONSORT Flow Diagram, Figure 3.1). The study 
population therefore consisted of 50 patients with a mean age of 73 ± 8 years. 
Demographic and medical characteristics were similar' in the RVA and RYOT 
groups (Table 3.1). There were no significant differences between the groups in 
terms of sex distribution, comorbidities, pacing indications, medical treatment 
and heart failure classification. Patients were randomised to either RVA (n=25) 
or RYOT (n=25) pacing. Follow up was performed on 22 patients (88%) in the 
RVA group (CONSORT Flow Diagram). One patient died due to an unrelated 
cause and the other two had serious adverse events (pericardial effusion on 
implantation). In the RYOT group, 23 patients (92%) completed the study 
follow-up. One patient died with an unrelated cause and one refused follow-up. 
Four patients (16%) allocated to have RYOT had RYA lead due to an inability to 
find a stable RYOT lead position with satisfactory parameters. These patients 
remained in the RYOT group for intention to treat analysis. However, if included 
in the RVA group, analysis was conducted on per protocol basis. On reviewing 
the chest X-ray (both postero-anterior and lateral) in the RYOT group, the right 
ventricular lead was positioned in the free RYOT wall in 10 cases, in the anterior 
RYOT in 9 cases, and in the RYOT septum in 2 cases.
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Figure 3.1: CONSORT flow diagram
Enrolment
Analysis
Randomised
Follow-up
Allocation
Analysed (n=22) Analysed (n=23)
Assessed for eligibility (n= 131)
RVA Pacing (n= 25) 
Received allocated 
intervention (n=25)
Follow-up (n=22) 
n=2 pericardial tamponade 
n=1 died (pulmonary fibrosis)
Follow-up (n=23) 
n=1 refused FU 
n= 1 died with metastatic 
carcinoma
Excluded (n= 81)
Not meeting inclusion criteria (n= 60) 
Refused to participate (n= 21)
RVOT Pacing (n=25)
Received allocated intervention (n=21) 
(n=4 inability to find stable RVOT position)
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3.2 Baseline characteristics of the whole study population
The study population consisted of 50 patients with a mean age of 73 ± 8. Thirty 
two patients were males (64%) and 18 females (36%). The mean BMI was 27.6 ± 
6. Table 3.1 shows the demographic and medical characteristics of the whole 
study population and that of each study group. This table demonstrates the 
distribution of patients between both study groups with regard to background 
medical history as well as medical treatment.
The mean NYHA class was 2.2 ± 0.6 in the whole study population with a mean 
Minnesota score of 48 ± 19. The mean QRS duration was 110 ± 22 msec. 
Baseline left ventricular ejection fraction (EF) varied between 40% and 77% 
(mean of 59 ± 7.8). All subjects had a left ventricular- end-diastolic diameter 
(LVEDD) of < 60 mm (mean of 48 ± 6). The mean Ex Time and peak oxygen 
consumption (PV02) were 371 ± 157 sec and 16.5 ± ml/kg/min consecutively.
Table 3.1: Baseline characteristics of the study population
Whole Study RVA Group RYOT Group
Mean ± SD Mean ± SD Mean ± SD
Age 73 ± 8.5 74 ±8 72 ±8
Males 32 (64%) 17 (68%) 15 (60%)
Females 18 (36%) 8 (32%) 10 (40%)
Height 170 ±8.2 171 ±7.8 170 ±8.7
Weight 80 ±21 79 ±23 82± 19
98
BMI 27.6 ± 6.3 26.8 ±7.3 28.4 ± 5.1
Hypertension 28% 30% 26%
Hyperlipidaemia 18% 20% 16%
Diabetes 12% 12% 12%
Smoker/ ex-smoker 19% 20% 18%
Previous MI 6% 10% 2%
Previous HF 4% 6% 2%
PVD 2% 2% 2%
Beta blocker 10% 10% 10%
Calcium antagonist 20% 22% 18%
ACE-I 17% 20% 14%
ARB 8% 10% 6%
Aspirin 20% 20% 20%
Clopidogrel 6% 10% 2%
Statin therapy 21% 24% 18%
Digoxin 7% 6% 8%
NYHA 2.2 ±0.6 2.2 ± 0.6 2.2 ±0.6
Minnesota score 48± 19 47 ±21 50± 17
QRSd (msec) 111 ±23 106 ±20 114 ±24
LYEDD (mm) 48 ±5.9 47 ±5.8 49 ±6
EF (%) 59 ±7.8 57 ± 7.4 60 ±8
Ex Time 371±157 366±180 378±131
PVO2 (ml/kg/min) 16.5 ±4.3 16.8 ±5 16.0 ± 3
Variables are presented as mean ± SD wlien appropriate
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3.3 Baseline characteristics of each study group
Baseline demographic and medical characteristics were similar in both RVA and 
RYOT arms (Table 3.1). Patients Sex distribution was well matched between the 
RVA and RYOT groups (2-sided P value - 0.55 on Pearson Chi-Square 
analysis). With regard to the previous medical background, history of 
hypertension, hyperlipidaemia, diabetes, and smoking were similarly distributed 
between both study groups. Five patients in the RVA group had a previous 
myocardial infarction with one patient in the RYOT group (2-sided P value = 
0.082 on Pearson Chi-Square analysis). Three patients in the RVA group had 
previous episode of heart failure with one patient in the RYOT group (2-sided P 
value = 0.30 on Pearson Chi-Square analysis).
Each arm had 14 patients with chronic high grade AY block and 11 patients 
listed to have ablation of the AY node as part of ablate and pace strategy, as seen 
in Table 3.2 (2-sided P value = 0.41 on Pearson Chi-Square analysis).
Table 3.2: Indication for pacing in each study group
Indication RVA group (n=) RYOT group (n=)
Persistent atrial fibrillation 4 7
Paroxysmal atrial fibrillation 6 3
Atrial flutter 1 0
Atrial tachycardia 0 1
AV block 14 14
Total 25 25
The majority of patients in both arms were patients in NYHA heart failure class 
II with no significant inter-group differences in NYHA baseline class (2-sided P
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value = 0.82 on Pearson Chi-Square analysis). All patients but one had either no 
mitral regurgitation (MR) or grade-I MR with no significant inter-group 
variation, as seen in Table 3.3 (2-sided P value = 0.89 on Pearson Chi-Square 
analysis).
Table 3.3: NYHA functional class at baseline in each study group
NYHA Class RVA group (n=) RVOT Group (n=)
I 2 3
11 16 14
III 7 8
Total 25 25
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3.4 Analysis of the cardiopulmonary exercise test data
The Cardiopulmonary Pulmonary Exercise Test was performed on 21 patients at 
the baseline (12 RVA and 9 RYOT) and on 34 patients at the follow up (17 in 
each study group). This was due to the fact that high grade AV block is a relative 
contraindication for CPET and that a significant proportion of the study 
population was elderly with functional limitation due to a non cardiac cause 
limiting their ability to ride on the cycle ergometer.
This study was not able to detect any significant improvement in exercise time or 
PVO2 (primary endpoint) in either arm or any inter-arm differences (Table 3.4 
and 3.5).
Table 3.4: Mean PVO2 at baseline and at follow up
Baseline 6 month FU P value
RVA 18.6 ±5.2 17 ± 5.1 NS
RYOT 15.8 ±3.6 14.9 ±4.1 NS
Table 3.5: Mean exercise time at baseline and at follow up
Baseline 6 month FU P value
RYA 382±184 333 ±207 NS
RYOT 369 ±137 340±161 NS
On comparing the changes (between baseline and FU) in PVO2 between arms, 
the average change was -1. 6 ± 3.9 in the RVA aim and -0.9 ± 2.7 in the RYOT 
arm, P = 0.95. As per protocol analysis revealed similar findings; the average
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change was -1.2 ± 3.8 in the RVA arm and — 1.3 ± 2.7 in the RYOT arm, P — 
0.76.
3.5 Analysis of NYHA class data
NYHA heart failure class analysis of the whole study population showed 
significant improvement; NYHA class dropped from 2.22 ± 0.6 at baseline to 1.6 
± 0.7 at the 6 month follow-up, P value < 0.0001 on Wilcoxon Signed Ranks 
Test. Table 3.6 shows the change in NYHA class in each study group. Figure 3.1 
is the Box and Whisker diagram representing the values of NYHA class in each 
study group.
Table 3.6: Mean NYHA functional class at baseline and at follow 
up
Baseline 6 month FU P value
RVA 2.23 ± 0.61 1,86 ±0.83 <0.001
RVOT 2.22 ± 0.67 1.43 ± 0.66 <0.001
RVOTRVOTRVA
Baseline NYHA
X 1st Quantile --Upper Unit e Median ♦Average - Low er Lirril x 3rd Quartilo
Figure 3.1: Box and Whisker diagram showing baseline and FU values of 
NYHA class in both study groups.
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On comparing the degree of improvement between the study groups (the degree 
of NYHA class drop in each arm), the intention to treat analysis showed no 
superiority in the RYOT arm. NYHA class dropped by a mean of 0,36 ± 0.78 in 
the RVA group and by 0.78 ± 0.67 in the RYOT group, P=0.08. When as per 
protocol analysis was performed, RYOT patients had significantly greater 
improvement; NYHA class dropped by a mean of 0.38 ± 0.80 in the RVA group 
and by 0.84 ± 0.60 in the RYOT group, P=0.04.
3.6 Analysis of Minnesota questionnaire score
MLWHF scores improved dramatically on FU in the whole study population. 
The mean score decreased from 48 ±19 to 22 ± 24, P < 0.0001 on Wilcoxon 
Signed Ranks Test. Table 3.7 shows the change in MLWHF scores in each study 
group.
We compared the degree of MLWHF score improvement between the study 
groups (the drop in the MLWHF score in each study arm). Table 3.7 shows the 
individual MLWHF scores for each individual study patient, while Figure 3.2 
represents the Box and Whisker diagram of the MLWHF scores in both study 
groups. The intention to treat analysis showed greater improvement in the RYOT 
arm; MLWHF score dropped by 21 ±22 in the RYA group and by 32 ± 19 in the 
RYOT group, P = 0.041 (Mann-Witney test). When as per protocol analysis was 
performed, RYOT patients had also significantly greater improvement; MLWHF 
score dropped by 22 ± 21 in the RVA aim and by 32 ± 20 in the RYOT arm, 
P=0.45 on Maim-Witney Test.
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Table 3.7: MLWHF score in both study groups
RVA Group RVOT Group
Baseline FU Baseline FU
14 3 3 0
17 3 13 NA
22 0 16 0
28 9 27 3
28 14 35 3
28 57 41 6
28 NA 43 34
30 30 45 2
31 4 47 9
34 NA 51 7
37 11 51 10
43 0 52 3
44 17 52 2
45 37 55 8
46 NA 57 4
50 7 59 16
52 21 59 0
52 56 60 68
60 3 61 22
65 62 61 27
68 31 62 55
78 70 63 26
79 5 70 NA
82 76 71 74
84 61 83 33
Mean 45,80 26.23 49.48 17.91
SD/ Cl 20.85/ 8.17 25.79/10.10 18.79/7.36 21.86/8.57
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Table 3.8: Mean MLWHF scores at baseline and at follow up
Baseline 6 month FU P value
RVA (n=22) 47.1 ±21.7 26.2 ±25.7 <0.001
RYOT (n=23) 50.1 ±17.4 17.9 ±21.8 <0.001
Figure 3.2: Box and Whisker diagram showing baseline and FU MLWHF scores 
in both study groups.
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3.7 Analysis of short form--36 health survey
This health survey covers the following quality of life aspects:
PF, Physical Function
RL, Role Limitation
BP, Bodily Pain
SF, Social Function
GMH, General Mental Health
RLEP, Role Limitation due to Emotional Problem
VEF, Vitality, Energy, or Fatigue
GHP, General Health Perception
HCLY, Health Compared To Last Year
SF-36 scores have improved dramatically on FU in the whole study population 
(Wilcoxon Signed Ranks Test). The only exception was in 2 areas: the Bodily 
Pain and the General Mental Health. Table 3.9 shows the change in SF-36 scores 
in each study group.
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Table 3.9: Short form-36 Health Survey mean scores on baseline and FU
Baseline score
(M ± SD)
FU score
(M ± SD)
2-sided
P Value
Wilcoxon
Test
Physical Function (PF) 36 ± 23 60 ±30 **
RVA 42 ±26 53 ±27 *
RVOT 31 ± 21 68 ±32 **
Role limitation (RL) 19 ±34 60 ±42 **
RVA 23 ±38 53 ±44 **
RVOT 14 ± 31 66 ± 40 **
Bodily Pain (BP) 68 ±28 69 ±27 0.9
RVA 69 ±27 68 ±25 0.9
RVOT 67 ±30 69 ±30 0.9
Social function (SF) 50 ±29 69 ±29 **
RVA 46 ± 31 64 ±32 **
RVOT 51 ±25 73 ±25 **
General Mental Health (GMH) 59 ±21 66 ±21 0.06
RVA 60 ±21 60 ±23 1
RVOT 57 ± 21 72± 18 *
Role Limitation due to Emotional Problem
(RLEP)
31 ±44
56 ±43 *
RVA 48 ±49 53 ±43 0.06
RVOT 17 ±36 60 ±43 **
Vitality Energy Fatigue (VEF) 36 ±20 54 ±22 **
RVA 40 ±21 47 ± 21 *
RVOT 34 ± 19 60 ±21 **
General Health Perception (GHP) 48 ±20 56 ±24 0.045
RVA 50 ±23 54 ±23 0.06
RVOT 44± 18 57 ±24 *
Health Compared to Last Year (HCTLY) 25 ±20 78 ±29 **
RVA 25 ±20 70 ±32 **
RVOT 24 ±22 85 ±25 **
(**) = P< 0.005
(*) = P < 0,05
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On comparing the degree of improvement between the study groups (the 
increases in the SF-36 scores), the intention to treat analysis using Mann- 
Whitney Test revealed a significant improvement in favour* of RYOT pacing in 
the following areas: (l)-Physical Function where the average increase in PF 
score was 11.2 ± 26 in the RYA arm and 36.6 ± 28 in the RYOT aim, P = 0,005. 
(2)- Role Limitation due to Emotional Problem where the average increase in 
RLEP score was 4.5 ± 54 in the RYA arm and 43.3 ± 46 in the RYOT aim, P - 
0.016. (3)- Vitality Energy fatigue where the average increase in VEF score was 
7.2 ± 24 in the RYA arm and 26.3 ± 27 in the RYOT arm, P = 0.024.
The same findings were shown when as per protocol analysis was performed. 
The P values of the differences in the following areas PF, RLEP, and YEF were 
0.001, 0.031, and 0.045 consecutively.
Tables 3.10, 3.11 & 3.12 show the PF, RLEP, and VEF scores for each 
individual study patient, while Figures 3.3, 3.4, and 3.5 represent the Box and 
Whisker diagram of these scores in both study groups.
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Table 3,10: Physical Function scores (SF-36)
RVA Group RVOT Group
Baseline FU Baseline FU
0 17 0 33
6 56 0 6
11 83 6 6
11 NA 6 11
17 33 6 89
17 28 11 100
22 22 11 61
22 NA 17 100
22 78 22 33
28 39 27 72
33 33 33 72
39 56 33 94
39 28 33 44
39 78 39 83
44 17 39 100
44 33 39 NA
44 NA 44 100
50 33 44 94
55 39 50 100
61 94 50 NA
66 72 50 33
72 67 56 72
72 100 61 89
94 94 67 83
94 72 72 94
Mean 40.08 53.27 32.64 68.22
SD/CI 25.84/10.13 27.12/10.63 21.35/8.37 32.86/12.88
<2. 60
__ V f , ,/T\
♦
47.5©
RVA Group
.03.0 ©
RVQT Group
* 1 st Guartile ™ Upper Unit o Median ♦Average
" Low er Lirrit % 3rd Quartile
Figm'e 3.3: Box and Whisker diagram showing baseline and PF scores in both 
study groups.
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Table 3.11: Role Limitation due to Emotional Problem Scores (SF-36)
RVA Group RVOT Group
Baseline FU Baseline FU
0 67 0 0
0 100 0 30
0 NA 0 100
0 0 0 0
0 0 0 100
0 NA 0 100
0 100 0 100
0 0 0 33
0 NA 0 100
0 33 0 0
0 0 0 NA
0 67 0 33
0 33 0 0
33 100 0 0
33 0 0 100
100 33 0 0
100 0 0 100
100 100 0 100
100 100 0 67
100 0 33 67
100 67 67 100
100 100 100 NA
100 100 100 67
100 67 100 100
100 100 100 100
Mean 42.64 53.05 20.00 60.74
SD/CI 48.61/19.05 43.2716.96 38.50/15.09 43.53/17.06
Baseline
RVOT GroupRVA Group
XlstQuartilB »• Upper Limit o Median ♦ Average
- Lower Limit X 3ro Quartile
Figure 3.4: Box and Whisker diagram showing baseline and FU RLEPS scores in 
both study groups.
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Table 3.12: Vitality Energy Fatigue Scores (SF-36)
RVA Group RVOT Group
Baseline FU Baseline FU
0 15 0 25
5 65 5 60
10 45 5 65
15 NA 10 75
25 50 15 70
25 20 15 NA
25 15 20 45
25 60 20 100
30 NA 25 65
30 65 30 30
30 NA 30 15
30 50 30 65
35 40 30 75
35 35 30 70
40 30 40 70
45 75 50 50
55 10 50 40
55 35 50 90
60 80 55 40
60 40 55 65
60 55 55 80
60 50 60 85
65 50 60 NA
65 70 60 40
75 90 65 75
Mean 38.40 47.50 34.60 60.65
SD/CI 20.60/8.07 21.80/8.54 20.20/7.91 21.60/8.46
60.7-
BaselineBaseline
RVOT GroupRVA Group
>K 1st Quartile “ Upper Unit o Median ♦ Average
- Low ar Unit X 3rd Quartile
Figure 3.5: Box and Whisker diagram showing baseline and FU VEF scores in 
both study groups.
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3.8 Analysis of electrocardiogram findings
On analysing the whole study population, QRS duration, as expected, has 
dramatically increased from a mean of 110 ± 22 msec on baseline to a mean of 
170 ± 20 msec on follow-up (P value < 0.0001 on Wilcoxon Signed Ranks Test).
We compared the QRSd prolongation between both arms (i.e. whether patients 
randomised to RVA pacing tend to have more QRSd prolongation). QRSd 
prolongation was not significantly more pronounced in the RVA group (P=0.91 
on intention to treat analysis and P = 0.25 on as per protocol analysis, Mann- 
Whitney Test).
When the post-implant ECGs in the RYOT group were analysed, negative or 
isoelectric QRS vector in lead I was seen in 43% of the RYOT implants.
We also reviewed the CXR in the RYOT group (both PA and lateral), acquired 
post pacemaker implantation. The right ventricular lead was positioned in the 
free RYOT wall in 10 cases, in the anterior RYOT in 9 cases, and in the RYOT 
septum only in 2 cases. The QRSd in the 2 septal RYOT positions were 179msec 
and 188mec.
3.9 Analysis of echocardiography findings
Echocardiogram data analysis revealed that the CARE-HF (Cardiac 
Resynchronisation in Heart Failure trial) echo dyssynchrony criteria were met in 
4 patients (2 in each aim) at the baseline assessment and in 11 patients at the FU
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(6 RYA and 5 RYOT). Two out of four patients with dyssynchrony on baseline 
(one in each ami), were found to have dyssynchrony on FU as well.
On analysing the whole study population (Wilcoxon Signed Ranks Test), EF 
dropped by 6.1%, from 59.1±7.8 to 53±8.8, PO.OOOl, mitral regurgitation (MR) 
grade dropped by 0,27 (P-0.007), APE was longer by 41 msec (PO.OOOl). The 
drop in LVOT-VTI was insignificant at 1.5 cm (from 21 dt 4 to 20 ± 6, P=0.058). 
We were unable to detect any significant change in LYEDD.
We analysed whether the changes (differences between the baseline and the 
follow up values) in the echocardiography parameters, were more pronounced in 
one arm more than the other. Both intention to treat and as per protocol analyses 
showed no difference between both arms (e.g. EF dropped by 7.2 ±6.2 in the 
RYA arm and by 5.17 ± 4.5 in the RYOT arm, P = 0.58)
Tables 3.13, 3.14 show the APED and IVD for each individual study patient, 
while Figures 3.6 and 3^represent the Box and Whisker diagram of these values 
in both study groups.
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Table 3.13: Aortic Pre-Ejection Delay in both study groups
RVA Group RYOT Group
Baseline FU Baseline FU
36 83 20 120
40 100 53 160
53 104 55 148
55 155 55 55
55 120 59 105
55 205 60 141
61 78 60 60
62 144 61 110
67 NA 63 135
71 130 63 131
75 114 64 122
80 163 65 65
80 126 74 122
83 185 83 104
90 140 85 85
95 115 87 144
100 168 90 130
100 122 98 NA
106 125 111 155
118 NA 115 150
125 144 127 126
130 NA 130 NA
147 104 143 136
147 147 155 104
NA 139 173 173
Mean 84.63 132.32 85.96 120.91
SD 31.85 31.16 37.09 31.60
132.3
120.9
74,0 ©
Baseline
RVOT GroupRVA Group
X 1 st Quartile — Upper Limit o Median ♦ Average
- Low or Limit X 3ra Quartile
Figure 3.6: Box and Whisker diagram showing baseline and FU values of APED 
in both study groups.
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Table 3.14: Interventricular Delay in both study groups
RVA Group RYOT Group
Baseline FU Baseline FU
-22 8 -45 30
-10 37 -39 41
-8 -5 -17 NA
-4 40 -14 -14
-3 39 -8 -8
0 80 -7 -7
4 65 3 -4
8 44 7 20
10 65 7 5
13 60 10 11
20 63 12 50
20 45 14 100
23 15 20 20
25 32 21 14
27 NA 25 55
29 NA 29 NA
33 80 30 81
35 38 40 48
40 NA 47 -14
44 44 50 15
50 50 53 50
50 22 54 48
51 -11 59 79
62 8 60 46
NA 35 67 20
Mean 20.71 38.82 19.12 29.83
SD 22.40 25.10 30.52 31.59
>; 1st Quarlilo - Uppar Unit o Median ♦Average
~ Low or Lirrit 3< 3rd Quarlilo
Figure 3.7: Box and Whisker diagram showing baseline and FU values of IVD in 
both study groups.
116
3.10 Analysis of other variables
Three patients had hospital admissions with symptoms of heart failure; all were 
in the RVA arm (this was not statistically significant, P=:0.13)
In summary, at 6 months, RYOT pacing was not superior to RVA in terms of 
PVO2. In contrast, RYOT pacing offered a more significant improvement in 
health-related quality of life scores, a feature that was strongly related to the 
superiority in NYHA class scores. Both RVA and RYOT pacing comparably 
worsened the echocardiogram parameters.
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CHAPTER FOUR
Discussion
The potential detrimental effects of RVA pacing have been well described. As a 
result, several large trials such as DAVID study have recommended 
minimisation of RVA pacing by using atrial based preferential pacing modes to 
maintain AVN conduction. However, in patients who require ventricular pacing, 
alternative sites have been postulated to be superior. The results of SSP trials 
have generally been disappointing with no consistent significant benefit being 
demonstrated at any one site. The results of our study do however add to an 
emerging evidence base supporting the utilisation of RVOT compared to RVA 
pacing.
In our study, the majority of those screened were excluded as they were elderly 
and frail with non-cardiac exercise limitation. This made recruitment difficult. 
Previous studies on SSP were conducted on small number of patients. In the 
study by Victor et al, investigators compared the haemodynamic effects of 
RVOT and RVA pacing in 16 patients with chronic atrial tachyarrhythmia and 
complete AV block over a 7 month period in a randomised crossover fashion 
(Victor et al. 1999), No significant differences were found in NYHA class, EF, 
exercise time, and PVO2. The small number of patients studied might explain the 
negative results. A larger randomised crossover study, (the ROVA study) was 
published in 2003 (Stambler et al. 2003) in which investigators compared RVA, 
RVOT, and dual site pacing in 103 patients with NYHA class II-III heart failure 
(EF < 40%) and chronic AF with a conventional bradycardic indication. The 
authors showed no difference in QOL between RVA, RVOT, or dual site pacing 
at 3 months. However, after 9 months, LVEF was higher (P=0.04) in those 
assigned to RVA rather than RVOT pacing. This significant difference noted at
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the 9 month follow up may be explained by the fact that LV remodelling may be 
a long process. As this study included only patients with LVEF < 40%, it is quite 
possible that pacing will result in more deleterious haemodynamic effects in 
comparison to patients with normal or near' normal systolic LV function.
Other small studies have however, provided positive results such as the study by 
Mera et al. They studied 12 patients undergoing His-bundle ablation for 
uncontrolled chronic AF and showed that septal pacing resulted in a narrower 
QRS, greater fractional shortening, and a greater resting LVEF than RVA (Mera 
et al. 1999). Another positive study was by Tse et al (Tse et al. 2002) where the 
investigators studied the effect of pacing site on myocardial perfusion and LV 
function by randomising 24 patients with complete AV block to receive RVA or 
RVOT leads. There was no difference between the two groups at 6 months, but at 
18 months, RVOT patients had a better EF, less perfusion defects and regional 
wall motion abnormalities. Unfortunately, both studies were conducted on 
relatively small numbers and did not assess patients QOL or functional capacity.
In our study, we were not able to detect any significant changes in PVO2 in either 
group or any inter-group differences. This may be attributed to the fact that 
CPET was performed on only 21 patients at baseline (12 RVA and 9 RVOT) and 
34 at the follow-up. Another compounding factor was the heterogeneity of the 
RVOT lead position; the right ventricular lead was positioned in the free RVOT 
wall in 10 cases, in the anterior RVOT in 9 cases, and in the RVOT septum in 2 
cases. This may reflect the large number of implanting physicians within our 
centre and the variation in practice and technique.
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Four patients randomised to RYOT actually received a RVA lead due to 
problems with stability and pacing parameters. Therefore, per protocol analysis 
was also performed as well as intention to treat. The results from per protocol 
analysis were only different in terms of NYHA classification which 
demonstrated a significant difference in favour of RYOT pacing. No statistical 
difference in the primary end point could be established using either form of 
analysis. Quality of life indices analyses revealed significant superiority of 
RYOT lead position on both intention to treat and per protocol analyses. 
Electrocardiogram analysis did not show any significant differences between the 
groups. This could be attributed to the fact that the RYOT lead was only 
fluoroscopically positioned. Finally, on echocardiography, there were no 
differences between the groups; again this may be explained by the relatively 
short follow-up and the fact that LV remodelling is a prolonged process.
All-cause mortality has only been evaluated retrospectively in one study by 
Vanerio et al in 2008 (Vanerio et al. 2008). They studied 150 consecutive 
patients who underwent pacemaker implantation for advanced AY block and 
symptomatic atrial fibrillation with slow ventricular response. During the mean 
follow-up of 3.4 years, 32% died in the RYOT group compared to 51% in the 
RVA group, p - 0.02. They concluded that RYOT pacing appears to improve 
medium-long term survival and recommended conducting prospective 
randomised trials to confirm these findings. This is clearly an observational study 
that was retrospectively conducted with all of the inherited potential confounders 
in such studies. The main confounder, in my opinion, is that the implanting 
physician is probably biased towards implanting RYOT leads in healthier and
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younger subjects. Although our study is a prospective one but it was not powered 
or designed to study a mortality difference especially with the relatively short 
follow-up of 6 months.
4.1 Statistical analysis
4.1.1 Statistical tests
In our study, nonparametric tests were used primarily to analyse the data as most 
variables were not normally distributed. Nonparametric tests are sometimes 
called distribution free statistics because they do not require that the data to fit a 
normal distribution. More generally, nonparametric tests require less restrictive 
assumptions about the data. Another important reason for using these tests is that 
they allow for the analysis of categorical as well as rank data (such as the NYHA 
functional class). However, parametric tests are often preferred because they are 
more robust and they have greater power efficiency, in other words, they have 
greater power relative to the sample size. Parametric statistical procedures 
assume that the variables are normally distributed. A significant violation of the 
assumption of normality can seriously increase the chances of committing either 
a Type I or II error (depending on the nature of the analysis and the non­
normality). Data transformation is utilised for improving normality. One way of 
data transformation is the logarithmic method. We applied this method to our 
non-normally data variables using SPSS and reanalysed the data using a 
parametric test. Both parametric and nonparametric tests, in our study, showed 
similar results. Independent samples T-test showed no difference between RVA 
and RYOT groups with regal'd to PV02, LVEDD, LVEF, and QRS duration (P -
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0.70, 0.81, 0.21, and 0.93 consecutively). On the other hand, RYOT was superior 
to RVA pacing in term of MLWHF scores. The drop in the score was more in 
RYOT group (mean 11, 95% Cl: -1 - 23, P = 0.04). RYOT was also superior in 
the same areas of SF-36. This includes: physical function (mean 25, 95% Cl: 8 - 
41, P - 0.003), role limitation due to emotional problem (mean 38, 95% Cl: 8 - 
69, P= 0.014), and vitality/energy/fatigue (mean 19, 95% Cl: 3 - 34, P = 0.019).
4.1.2 Bonferroni correction
In our study we performed 40 clinically significant comparisons between study 
groups. Therefore, the expected number of spurious significant results is 40 times 
0.05 = 2. It is mandatory to be aware of attaching too much importance to a lone 
or few significant results among a mass of non-significant ones. It may be the 
one in twenty which we should get by chance alone. This is particularly 
important when we find that a clinical trial or epidemiological study gives no 
significant difference overall, but does so in a particular subset of subjects, such 
as in a certain age group. We can allow for this effect by the Bonferroni method. 
In general, as we are testing at 5% significance level, then the corrected 
significant level will be 0.05/number of comparisons. Therefore, in our study the 
corrected significant level will be 0.05/40 = 0,00125.
4.2 Study population age group and comorbidity
There are many challenges inherent in conducting clinical trials in elderly 
patients. One of the most frequently reported problems involves travelling to the 
clinic or research site. Factors such as transportation availability, complexity of 
directions, and the time and cost that are required in travelling, are all labelled as
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possible deterrents to participation. Another problem relates to the nature of the 
inclusion/exclusion criteria. Also, this population is also much more likely to 
have, or develop during the course of the study, comorbid medical conditions 
that will result in their exclusion or drop out. After the recruitment phase, the 
next task of the investigator(s) involves the retention of the selected patients to 
ensure adequate monitoring and recording of the variables of interest (Cassidy, 
Baird, & Sheikh 2001; Macias, Ramsay, & Rowan 2007).
In this study the follow up was not performed on 5 patients (10%). Two patients, 
one in each study group, died with an unrelated cause. One patient in the RVOT 
group refused follow up, while 2 patients in the RVA group had serious adverse 
events (pericardial tamponade) as a result of the pacemaker implantation 
procedure. This is a much higher than average rate of pericardial tamponade in 
the RVA (2/25) group. Liverpool Heart and Chest Hospital implants an average 
of 1000 new pacing systems per year with an average rate of 1/500 cases of 
pericardial tamponade. There are 10 consultants and 6 registrars implanting at 
any one period in time. The high rate of this complication in the RVA group can 
only be explained by pure chance as it was the same implanting physicians who 
also implanted in the study patients. RVOT septal pacing has the theoretical 
advantage of avoiding pericardial effusion secondary to myocardial perforation 
as the pacing lead is fixed to the interventricular septum. As the rate of this 
complication is very low, this theoretical advantage is not yet proven in 
prospective randomised trials.
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4.3 Poor definition of right ventricular outflow tract
Attempts to define the RYOT have been the subject of extensive debate. No 
universal definition of site has been agreed. The term has been used to describe a 
variety of pacing sites including the true outflow tract, the mid septum, and the 
anterior region above the apex (Mond et al. 2007). This confusion persists 
despite attempts to standardise the nomenclature of nonapical pacing sites 
(Lieberman et al. 2004). Consequently, the resultant acute and chronic studies of 
RYOT pacing have produced conflicting results making interpretation of the 
published literature difficult. Furthermore, even when the true RYOT is 
considered, the anatomy is complex and many studies do not distinguish between 
different sites within this structure (McGavigan et al. 2006), which may be 
important, as activation patterns and wavefront propagation will depend on the 
pacing site within this large area of the right ventricle.
In our study, the RYOT was only defined fluoroscopically, not 
electrocardiographically. When the post-implant ECGs in the RYOT group were 
analysed, negative or isoelectric QRS vector in lead I was seen in 43% of the 
RYOT implants. This ECG finding has a 90% positive predictive value for 
RYOT septal placement (McGavigan et al. 2006). Surprisingly, this feature has 
not shown any correlation with a shorter QRSd in our study. We also reviewed 
the CXR in the RYOT group (both PA and lateral), acquired post pacemaker 
implantation. The right ventricular lead was positioned in the free RYOT wall in 
10 cases, in the anterior RYOT in 9 cases, and in the RYOT septum only in 2 
cases. This heterogeneity in lead position might account for heterogeneity in 
patients’ clinical response.
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4.4 Cardiopulmonary exercise test data
Assuming that RYOT pacing can preserve the LV haemodynamics and therefore 
produce better cardiac output, this should be reflected in a better functional 
performance in patients receiving RYOT rather than RVA lead. The overall 
functional performance can be objectively assessed by measuring the peak 
oxygen consumption (PVO2) on CPET. Only one of the previous studies 
comparing RYOT with RVA pacing has included PVO2 as a study outcome 
(Victor et al. 1999). In this study 16 patients with chronic atrial tachyarrhythmia 
and complete AY block were included. LVEF was > 40% in 10 and < 40% in 6. 
Patients were implanted with a standard DDDR pacemaker connected to two 
ventricular leads. A screw-in lead was placed at the RYOT and connected to the 
atrial port. A second lead was positioned at the RVA and connected to the 
ventricular port. Right ventricular outflow tract and RVA pacing was achieved 
by programming either the AAIR or the VYIR mode respectively. Four months 
later patients were randomised so as to undergo either RYOT or RVA pacing for 
three months according to a blind crossover protocol. Apart from the pacing 
mode, programming remained unchanged throughout the study. At the end of 
each period, NYHA class, LYEF, exercise time and PVO2 were assessed. No 
significant difference was observed between the two modes for all the parameters 
analysed. These results were observed in all patients globally, in patients with 
LVEF > 40% as in those with LVEF < 40%. It is possible in this study that the 
presence of two ventricular leads has affected the right ventricular 
haemodynamics by inducing tricuspid regurgitation especially in those with 
LYEF < 40%. It is also important to be aware that this study was not powered to 
differentiate between patients with LVEF < 40% and those with LVEF > 40%.
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In our study, CPET was performed on 21 patients at the baseline (12 RVA and 9 
RYOT) and on 34 patients at the follow up (17 in each study group). We were 
not able to detect any significant improvement in exercise time or PV O2 (primary 
endpoint) in either arm or any differences between the study groups. The 
relatively small number of patients completing cardiopulmonary exercise test at 
baseline was very disappointing to the investigators. The initial inclusion criteria 
included only patients with AF who were listed for ablation of the AV node and 
pacemaker implantation. Due to initial slow recruitment, the inclusion criteria 
had to be expanded to include other patients who were in need of permanent RV 
pacing, such as patients with chronic AY block. Unfortunately, PVO2 was not 
measured at baseline in such cases because CPET is a relative contraindication in 
this group and that a significant proportion of the study population was elderly 
with functional limitation due to a non cardiac cause limiting their ability to ride 
on the cycle ergometer. This undoubtedly contributed to the fact that no 
significant difference in the primary end point was demonstrated.
The predictive value of PVO2 is accurate only when exercise capacity is limited 
by heart failure. Factors that can prematurely terminate the test should be 
excluded, including significant peripheral muscular deconditioning, peripheral 
arterial disease, arthritis, angina pectoris, or low patient motivation. All tests 
should be performed under standard conditions. It is possible that our study 
missed a real difference between the study groups in terms of PVO2 because of 
the relatively small study sample or the relatively short follow-up that was 
insufficient to permit LV remodelling.
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4.5 Quality of life data
Biventricular pacing is currently indicated in patients with heart failure. Large 
randomised controlled trials have demonstrated significant benefits in terms of 
functional capacity, QOL, hospitalisation and more recently mortality (Cleland et 
al.) With respect to patients undergoing pacemaker implantation for a 
bradycardic indication, only the ROY A study (Right ventricular Outflow Versus 
Apical pacing) trial (Stambler et al. 2003) has evaluated the potential impact of 
different pacing sites on QOL. The primary purpose of this cross-over trial was 
to determine whether pacemaker recipients with CHF, LV systolic dysfunction, 
and chronic atrial fibrillation have better quality of life (SF-36 questionnaire) 
during chronic pacing from the RYOT than the RVA. At 6 months, the RYOT 
group had higher (P = 0.01) role-emotional QOL subscale scores than the RYA 
group. At 9 months, there were no significant differences in QOL scores between 
RYOT and RVA groups. Comparing RYOT to RVA pacing within the same 
patient, mental health subscale scores were better (P=0.03) during RYOT pacing. 
The ROY A investigators concluded that in patients with CHF, LV dysfunction, 
and chronic AF, RYOT and dual-site RV pacing do not consistently improve 
QOL compared with RYA pacing.
The patients in our study were fundamentally different to those in the ROY A 
study in that they had preserved left ventricular function at baseline evaluation. 
However, all patients had either advanced AY block or uncontrolled atrial 
arrhythmia requiring AY node ablation. This explains the significant 
improvement in NYHA heart failure class and quality of life scores after 
implanting a permanent pacemaker regardless of the RV lead position. However,
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the main purpose was to examine whether the magnitude of change in QOL was 
different between those patients in the RVA and RVOT groups. Minnesota 
LWHF scores improved significantly by 32 ± 19 in the RVOT group and by 21 ± 
22 in the RVA group, P=0.041. Additionally, SF-36 health scores improved 
significantly more in the RVOT pacing group as compared with the RVA group. 
Interestingly, the between group analysis showed an insignificant difference in 
the change in NYHA class on intention to treat, P = 0.08. In contrast, per 
protocol analysis showed significant improvement in favour of RVOT pacing, P 
= 0.04.
Alternative studies have evaluated the effects of para-Hisian pacing compared to 
RVA pacing. One positive trial with relation to the QOL was reported in favour 
of para-Hisian pacing (Occhetta et al. 2006). In this study, permanent para-Hisian 
pacing in patients with chronic atrial fibrillation and narrow QRS who underwent 
atrioventricular (AV) node ablation was compared with RVA pacing in 16 
patients. Clinical and echocardiographic data were collected at baseline and after 
two randomised six-month periods (with para-Hisian and conventional pacing). 
Para-Hisian pacing allowed an improvement in NYHA functional class (1.75 ± 
0.4 vs. 2.33± 0.6 at baseline and 2.5 ± 0.4 during apical pacing, p < 0.05 for 
both), in quality-of-life score (16.2 ± 8.7 vs. 32.5 ± 15.0 at baseline, p < 0.05).
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4.6 Echocardiography data
In our study, analysis of the whole population revealed a reduction in ejection 
fraction of 6.1%, P < 0.0001 and mitral regurgitation grade by 0.27, P=0.007. 
The changes in left ventricular ejection fraction and mitral regurgitation grade 
were similar in the study groups, on both intention to treat and as per protocol 
analyses. In addition, The CARE-HF (Cardiac Resynchronisation in Heart 
Failure) echo dyssynchrony criteria were similarly met in both RVA and RYOT 
pacing groups. In summary, both pacing sites were equally harmful in terms of 
LVEF, dyssynchrony and mitral regurgitation severity.
It is well known that chronic right ventricular apical pacing worsens left 
ventricular systolic function (Buckingham et al. 1998). Right ventricular outflow 
tract pacing has been introduced to avoid this complication of RVA pacing. It is 
assumed that a more normal ventricular activation brings out less deterioration in 
the LV function. Despite this theoretical advantage, various clinical reports did 
not show convincing data of the superiority of mid-term RYOT pacing over 
RYA pacing (de Cock et al. 1998; Stambler et al. 2003; Tse et al. 2002; Victor et 
al. 1999). Ten Cate et al assessed the acute effects of RVA and RYOT pacing on 
LVEF in order to determine the contribution of echocardiography for the 
selection of the optimum pacing site during pacemaker implantation (ten Cate et 
al. 2008). They studied 14 patients with a DDD-pacemaker (7 RVA, 7 RYOT) 
and normal LVF without other cardiac abnormalities. They concluded that both 
acute RVA and RVOT pacing negatively affect wall motion score, longitudinal
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LV strain, and mechanical activation times, without clear differences between 
both pacing sites.
It is possible that RYOT superiority may become evident only if His bundle is 
targeted and that non-His bundle RYOT sites can induce LV dyssynchrony as 
much as RV apex pacing. In one acute study (Padeletti et al. 2007), 12 patients 
with a standard indication for electrophysiological study were evaluated. A 
pressure-volume catheter was positioned in the left ventricle. Pressure-volume 
loops were collected during atrial (AAI) and dual-chamber overdrive pacing at 
82 ± 15 beats/ min after 2 minutes of haemodynamic stabilisation. Ventricular 
pacing catheter position was randomised between the RV apex, RV septal, and 
free wall portions of the outflow tract, LV free wall, and His bundle. His bundle 
capture was verified from surface electrocardiographic morphometry using 
standard criteria. LV only pacing, but not His pacing, resulted in improved stroke 
work and stroke volume compared with alternate site RV pacing. No changes in 
H-dP/dt, LV end-systolic pressure, LV end-diastolic pressure, or cycle efficiency, 
were observed between RV pacing sites. They concluded that acute His bundle 
pacing did not improve LV function compared with alternate site RV pacing and 
may be inferior to LV pacing.
Long-term improvement in LV function after direct His bundle pacing was only 
seen in a small study involving 18 patients with dilated cardiomyopathy, chronic 
AF, and QRS <120 msec (Deshmukh et al. 2000). In their study, LVEDD 
reduced from 59 ± 8 mm to 52 ± 6 mm (P < 0,01) with an accompanying 
increase in left ventricular ejection fraction from 20 ± 9% to 31 ± 11 % (P < 
0.01).
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4.7 Study limitations
1- The PVO2 results could have been confounded by the fact that the mean age of 
the study population was 73 year’s and therefore participants were possibly 
restricted physically by other systems rather than the cardiac performance such 
as pulmonary or musculoskeletal pathologies.
2- The power calculation was done by referring to previous small studies with 
peak oxygen consumption as an endpoint. We had also to refer to other studies 
on cardiac resynchronisation therapy to agree on the minimum clinically 
significant difference in peak oxygen consumption to be able to do the power 
calculation of the sample size. It may be inappropriate to do such thing as cardiac 
synchronisation is indicated in a completely different group of patients with 
advanced heart failure and poor left ventricular function. We then estimated that 
25 patients are needed in each study group to reach the required power of 90%.
3- As patients5 recruitment was slow we had to expand the inclusion criteria to 
include patients with atrioventricular block. It is inappropriate to exercise such 
patients as they have chronotropic incompetence and therefore exercise test is a 
relative contraindication in such cases. Consequently, CPET was only performed 
in 21 patients out of the total 50. This has therefore underpowered the study and 
made it susceptible to type II error (no difference between the study groups was 
found when there is actually a difference).
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4- Four patients crossed over from the RYOT group to the RVA group. This was 
explained by the inability to find a stable and satisfactory RYOT pacing site. 
However, it is possible that the relative inexperience of the implanting physician 
was a contributing factor. In an attempt to overcome this challenge, both 
intention to treat and per treatment received analyses were performed.
5- Five patients in the RVA group had previous myocardial infarction with only 
one in the RYOT group. Although P value was insignificant at 0.08 but this 
could be an important clinical factor that could affect study outcomes. It is 
however reassuring that the baseline LV ejection fraction was well matched 
between both study groups.
6- The RYOT group had more patients with persistent atrial fibrillation 
compared to the RVA group (RVOT/RVA = 7/4). This meant that dual chamber 
pacing was used more in the RVA group.
7- The RYOT lead was positioned on fluoroscopy only and no specific part of 
the RYOT was targeted. This may possibly explain the fact that on retrospective 
review of the chest X rays, the right ventricular lead was positioned in the free 
wall in 10 cases, in the anterior wall in 9 cases, and in the septum in 2 cases only. 
This heterogeneity in RYOT lead position may also explain the fact that QRS 
duration was similar in both study groups. It is also worth mentioning that when 
the post-implant ECGs in the RYOT group were analysed, negative or isoelectric 
QRS vector in lead I was seen in 9 out of 21 of the RYOT implants which was 
suggested to correlate with septal pacing. Therefore, in our study there was no
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clear correlation between fluoroscopy and ECG signs of septal pacing. This can 
possibly be explained by the fact that previous studies were conducted on 
different group of patients with variable characteristics.
8- Echocardiographic variables were similar in both study groups. It is possible 
that negative LY remodelling and therefore LV ejection fraction could take years 
to significantly change, especially that the baseline LVEF was 59% in the study 
population. Another possible confounder is that the intra-observer variability is 
well described in the assessment of LV function via echocardiography.
9- With regal'd to LV dyssynchrony assessment, we used simple criteria that 
were previously used in trying to select heart failure patients for biventricular 
pacemaker implantation. It is possible that as our patients were of completely 
different characteristics and that the majority have normal or near normal LV 
function that these dyssynchrony criteria is not applicable. Actually, even in the 
field of selecting patients for cardiac resynchronisation therapy, a recent multi­
centre trial (PROSPECT) showed that there is no single echocardiographic 
measure of dyssynchrony may be recommended to improve patient selection for 
CRT beyond current guidelines.
10- The main positive finding in our study is the QOL difference between the 
study groups. Although QOL is a relatively soft and subjective endpoint, it might 
be more relevant to this age group of patients than the echocardiogram 
parameters which are usually seen as harder endpoints. In addition, NYHA 
functional class was estimated by the investigator at baseline and follow-up
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instead of an evaluation by an independent investigator. In an attempt to avoid 
bias, baseline investigations were done before randomisation while follow-up 
investigations were performed by investigators with no access to the allocated/ 
received treatment. The investigator is also at risk of subjectively deciding on 
NYHA class as all clinicians are aware of borderline cases where it is difficult to 
decide whether it is NYHA class II or III. There is also significant inter and intra 
observer variability which becomes more relevant when subjects are unable to 
read the questionnaire and the researcher had to read these questions loud. This 
becomes even more relevant in elderly patients who are hard of hearing.
11- Although the use of SF-36 appears to be the most validated among generic 
questionnaires because of its psychometric characteristics, the MLWHF 
questionnaire has only been used in patients with heart failure to measure their 
response to either medical or device intervention. This clearly does not apply to 
our study patients as they were mainly patients with good LV function and in 
NYHA class II.
12- Pacemaker implantation in patients with advanced AY block and in those 
who had “ablate and pace” for uncontrolled AF will clearly have a significant 
positive impact on their QOL scores. Therefore, detecting possibly a smaller 
impact secondary to the position of the RV lead will be confounded by the larger 
improvement secondary to giving them a pacemaker.
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CHAPTER FIVE
Conclusion & Recommendations
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The right ventricular apex has been the default pacing site since 1959 with many 
patients surviving with 20-30 year old follow-up assessments. However several 
trials have suggested that right ventricular pacing can cause deleterious 
consequences such as left ventricular dilatation and negative remodelling. Other 
randomised controlled trials have demonstrated that a high percentage of right 
ventricular apical pacing was strongly predictive of higher incidence of adverse 
clinical outcomes such as heart failure hospitalisation, atrial fibrillation, 
thromboembolic complications, and even death. It is unclear whether it is pacing 
the right ventricle or the right ventricular apex that is the actual problem. It was 
therefore recommended that pacing the right ventricle should be minimised. 
However, programming strategies are not relevant in patients with advanced 
atrioventricular block or patients who have undergone atrioventricular node 
ablation who require permanent ventricular pacing. This has led to evaluation of 
alternative right ventricular pacing sites in order to achieve a more 
“physiological” pattern of ventricular activation. The most studied of these sites 
has been the right ventricular’ outflow tract.
Within the limitations of our study, RVOT pacing, at 6 months, was not superior 
to RVA in terms of PVO2. In contrast, RVOT pacing offered a more significant 
improvement in health-related quality of life scores. Both RVA and RVOT 
pacing comparably worsened echocardiogram parameters. Our study therefore 
adds to the limited evidence that is available in relation to SSP. It provides 
further support for the emerging benefits of RVOT compared to RVA pacing.
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We recommend conducting a better designed trial by only including patients post 
AV node ablation. This would permit all patients to be evaluated in terms of our 
primary outcome measure. The study should also allow us to calculate sample 
size for both: patients with preserved or impaired LV systolic function. The 
chance of cross over can be minimised by training junior doctors on how to 
implant the lead into the right ventricular out flow tract and familiarising them 
with the different fluoroscopic projections and the electrocardiographic that 
could be specific to one particular site such as the RYOT septum. It is possible 
that better future tools will allow a more successful delivery of pacing leads to 
the targeted RYOT site.
The follow up should be at least 18 months and preferably 24 months. This 
would allow time for the potentially prolonged remodelling processes to take 
place. This is quite important as the suggested patients’ cohort have a well 
preserved LV systolic function and therefore the longer the follow up, the more 
chance of finding a difference between the study groups if a real difference 
actually exists. Echocardiogram assessment of the LV function should be ideally 
done using contrast to minimise the intra- and inter-observer variability. In 
addition, we could utilise more sophisticated methods of assessing LV 
dyssynchrony including tissue Doppler techniques which may have more 
sensitivity in detecting signs of dyssynchronous LV contraction. The other way 
forward in the field of searching for a better RV pacing site, if one exists, is 
conducting a well designed large multi-centre trial. The primary outcome should 
be a clinical one such as time to hospitalisation, occurrence of atrial fibrillation, 
or even death. This will require a huge amount of financial support which may be
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very difficult to find as the industry has no financial incentive to invest in such 
large study unless it involves new techniques that could make it financially 
viable for them.
Another very important point is that so far there has been no study of non-RV 
apical sites that showed a detrimental effect of these sites when compared to RV 
apical pacing (SSP is not inferior to RVA pacing). Actually, all previous trials 
revealed either a neutral outcome or were in favour of non-apical pacing site. The 
pacing community should also be fully aware of the publication bias as 
“positive” trials have more chance reaching the wider audience. Meanwhile, it 
would seem logical to abandon the right ventricular apex as a default pacing site 
and train the next generation of junior implanters to target non-apical site so they 
would be better equipped for a possible future change in practice.
5.1 General lessons learnt by the researcher
Dedication
I have learnt that a prolonged period in research should not be undertaken lightly. 
The difference from a structured training program is disconcerting. You initially 
feel lost in the whole process. There is so much new to learn but there appears to 
be so much time. Having spent considerable time on background reading and 
under taking statistics courses I became engrossed with producing a review 
article which would form the basis of my introduction. I had not appreciated the 
importance of fully understanding the nuances of methodology and the difficulty
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of performing high quality clinical research. I was to find myself frustrated with 
the clinical services, colleagues and ultimately myself. The initial difficulty in 
recruiting patients was to be dwarfed by the difficulty in collecting complete data 
for each and every patient. This really came to light during analysis where I 
found myself reliant on the help of others once more. I spent many long hours 
trying to understand statistics and even more hours writing up late at night. This 
was to the detriment of my wife and yoimg family without whose understanding 
I could not have completed my thesis. I have found my period in research 
extremely challenging but ultimately very rewarding. Without regular meetings 
with my supervisor and occasional kind and understanding advice I would have 
struggled.
Methodology
The most important thing that I have leant about research is that the methodology 
must be appropriate and feasible. An understanding of the background is vital in 
order to formulate a hypothesis which will have relevance to clinical practice. 
Whilst it is possible to define a patient population exactly, it is not always 
possible to find such patients in clinical practice. Whilst it is also easy to define a 
clear and objective endpoint, it is not always possible to measure this in all your 
patients. This can create enormous frustration and place stress on a researcher. 
One has to be true to both best clinical practice in the interest of the patient and 
best research practice in the interest of the project. This can create conflict and I 
found this difficult to cope with. I was helped by senior colleagues and
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supervisors alike. When planning future clinical research I will consider very 
carefully the clinical framework within which I will have to adapt.
Time Management
Time in research initially seemed ample although there was much to do and 
learn. However, once recruitment stalled I was initially excited and invigorated 
but soon found myself torn between recruiting new patients and fitting in follow 
ups. There did not seem to be enough time in the day. I was always disappointed 
to find I had missed a potential patient especially if I had been busy with 
something else. Once data analysis started I then had to make deadlines for 
abstract submission, the process of which was more testing than producing the 
work itself. I was often asked to cover clinical sessions for colleagues. This was 
initially fine but later had to be declined. I found it difficult to step back from 
clinical work especially procedure sessions as I was concerned that I would de- 
skill. Fortunately I have not but I have had to work extremely hard to write up 
having returned to a full time clinical job. This was not an ideal situation and an 
extension to my time in dedicated research may have been considerably easier.
People Skills
Research has taught me to understand patients and their fears much more. The 
process of informed consent required detailed explanation and discussion of 
potential complications. I think this will help me in my future clinical practice. I 
also had to understand that the focus of those in clinical practice is to provide a
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high quality and efficient service. This did not always help with patient 
recruitment for research especially if there was no potential benefit to clinical 
colleagues. I therefore had to learn the importance of educating colleagues, 
secretaries, physiologists, nurses and bed managers to inform me if a potentially 
appropriate patient had been listed. I also realised the benefits of making coffee 
and providing biscuits as bribes.
University Regulations
The rules regarding the completion of an MD thesis must be adhered to exactly 
and need to be read and understood at an early stage. This was low on my list of 
priorities but was insisted upon by my supervisors. Interim reports had to be 
completed in time and needed to be concise and relevant. Lessons learnt from 
discussions at such meetings helped mould my final project which had to be 
altered as it progressed. Without following the correct procedure this would not 
have been possible.
Data Collection
As pail of my study, considerable time and effort had been put into formulating a 
Case Report Form for each patient. This meant that transcription of relevant 
research data was efficient and appropriate. Despite this it was easy to miss a 
single piece of vital information which was time consuming to remedy. Hospital 
notes can vanish for weeks at a time. I had to be meticulous in collecting 
complete data at every patient visit. Where it was not possible to collect some
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data on clinical grounds there was considerable impact on the statistical analysis 
for individual endpoints. This reinforces my opinion that all research is only as 
good as the methodology.
Statistical Analysis
Having completed several statistical courses and digested a book I felt I had a 
rudimentary understanding of the topic and would be able to analyse my data in a 
reasonable manner. However on my initial attempt it was clear that data does not 
always follow the rules. I am most grateful for the advice and time of those with 
experience in statistical analysis of clinical data. It was easy to produce copious 
amounts of p values but understanding which was appropriate and relevant was 
more of a challenge. I feel that I know and understand the results from my study 
in great detail which can only come from taking ownership of the analysis. I have 
learnt that parametric tests are often preferred because they are more robust and 
they have greater power efficiency, in other words, they have greater power 
relative to the sample size. In addition, a significant violation of the assumption 
of normality can seriously increase the chances of committing either a Type I or 
II error. Finally, it is mandatory to be aware of attaching too much importance to 
a lone or few significant results among a mass of non-significant ones. This can 
be avoided by adjusting the significance level using Bonferroni method.
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Writing up
In the early stages of my research I was asked to write a review article by my 
supervisor. This meant I had to do back ground reading a produce my first ever 
manuscript. This helped me understand the fundamental issues to be addressed in 
my thesis and also to place my work in the context of that already published. 
After several drafts and rejection from a journal I realised that this was a skill I 
would have to work on. I learn to persist with article writing and submission. I 
also learnt to adapt an article according to the requirements of an individual 
journal. I became more successful as time passed. The same process had to be 
applied to abstract submission and although rejection was always disappointing 
the joy of acceptance made it bearable. When it came to thesis writing however, 
the detail and formatting required was altogether different. Nevertheless I am 
proud of what I have learnt and achieved.
5.2 Study specific lessons learnt be the researcher
RVOT Definition
We should have been more specific in defining RVOT pacing by not only relying 
on the fluoroscopic definition but on the electrocardiographic findings as well. 
By doing so we can be more confident about which part of the RVOT is targeted. 
Implanting physicians should have been introduced to this study and formally be 
trained in how to reach the RVOT and more specifically perhaps the RVOT 
septum prior to the recruitment phase.
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The Inclusion Criteria
It is possible that the inclusion criteria should not have been modified as simply 
by its expansion the power calculation was invalidated and this put the study at a 
risk of type II error. Perhaps it would have been favourable to recruit patients 
from other implanting centres rather than adjusting the inclusion criteria. It is 
also possible that the quality of life parameters would have been more relevant in 
our patients’ age group than the peak oxygen consumption as the measurement of 
the later may be confounded by the multiple comorbidities encountered in such 
age group. Other potential confounders are: previous myocardial infarction, 
history of PAF and its duration, lead position on the lateral CXR which was done 
after pacemaker implantation, being on antiarrhythmic drugs at the time of 
implantation in particular amiodarone.
The Follow-up
The study follow-up should have been done at 6 months as well as 18 months to 
account for the possible long term left ventricular remodelling. Echocardiogram 
parameters should have been assessed by two independent investigators after 
formally assessing the inter- and intra-observer variability.
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5.3 Implications for clinical practice
Although our study added to the existing evidence it remains a relatively small 
study with a medium-term follow up that was conducted in a single centre. It is 
therefore unlikely to change clinical practice. It will however encourage more 
device implanters to at least think about where to position the RV lead rather 
than targeting the RV apex at al times. The RYOT will always have the 
theoretical advantage that it is less likely to cause pericardial tamponade. 
However, the skills required for targeting the RYOT take longer to acquire with 
probably higher rate of failure. In my practice RYOT pacing has a 5-10% failure 
rate either because the site is electrically inadequate or it is impossible to fix the 
lead to the targeted area. It is possible that future multi-centre studies on selective 
site pacing will prove the superiority of RYOT lead as a default position for the 
RV lead. It may be more appropriate for the RY apex to be targeted in special 
subgroups, when the implanting physicians are at the beginning of their career, or 
are simply general cardiologists who were trained in the “traditional” manner. 
Finally, this study may help to influence the training of future generations of 
device implanters to incorporate RYOT pacing as a primary implant site.
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Appendix 1
The Cardiothoracic Centre - Liverpool
NHS Trust
Liverpool 
L143PE
Telephone switchboard 0151 228 1616
Participant Consent Form
Study Number: 695
Patient Identification Number for this trial (CRF No.):
Title of Project: A study evaluating the effects of Selective Site Ventricular Pacing on 
the haemodynamic and functional recovery of patients following atrio-ventricular 
nodal ablation. (SSP-1 study)
Name of Researchers: Dr Khaled Albouaini/Dr Jay Wright
Please initial box
1. I confirm that I have read and understand the information sheet dated 
14,h June (version 2) for the above study and have had the 
opportunity to ask questions
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. □
3. I understand that sections of any of my medical notes may be looked 
at by responsible individuals from the Clinical Trials Unit at 
cardiothoracic centre NHS Trust or from regulatory authorities where 
it is relevant to my taking part in research. I give permission for these
□
4. I agree to take part in the above study. □
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
3 copies to be signed: 1 for patient; 1 for research files: 1 for casenotes.
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Appendix 2
The Cardiothoracic Centre - Liverpool E2
NHS Trust
Patient Information Sheet Thomas Drive,
Liverpool, L14 3PE
Centre Number:
Study Number: 695
1. Study title
A study evaluating the effects of Selective Site Pacing on the haemodynamic 
and functional recovery of patients requiring permanent right ventricular pacing 
(SSP-1 study)
2. Invitation paragraph
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part.
Thank you for reading this.
3. What is the purpose of the study?
The heart's "natural" pacemaker is called the sinoatrial (SA) node or sinus node 
which is a small mass of specialized cells in the top of the heart's right atrium 
(upper chamber) that makes the electrical impulses that cause the heart to beat. 
A chamber of the heart contracts when an electrical impulse moves across it 
and for the heart to beat properly, the signal must travel down a specific path to 
reach the ventricles, the heart's lower (pumping) chambers. The natural 
pacemaker may be defective, causing the heartbeat to be too fast, too slow or 
irregular or the hearts' own electrical pathways may also be blocked. An 
"artificial pacemaker" which is a small, battery-operated device that helps the 
heart to beat in a regular rhythm can be prescribed.
Traditionally pacemaker implantation has been achieved by the secure 
positioning of electrical leads at the top of the right atrial appendage (RAA) and 
at the tip of the right ventricle commonly described as right ventricular apex 
(RVA). Although this type of pacing maintains a regular heart beat and rhythm it 
results in the abnormal contraction in the left ventricle which may place the 
patient at increased risk of heart failure. Other sites such as the area around the 
opening of the right ventricle commonly described as the right ventricular outflow 
tract (RVOT) have been considered. However, other investigations evaluating 
alternative pacing sites have provided conflicting results and no firm conclusions 
have been drawn. We therefore propose for the first time to study the impact of
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the traditional RVA pacing as compared to RVOT pacing on the improvement of 
patient's exercise capacity and cardiac function during exercise in a population 
of patients with similar disease background that require constant ventricular 
pacing.
4. Why have I been chosen?
You have been chosen because you have either
* Irregular heart beat which require treatment with an ablation procedure of 
the atrio-ventricular node and the implantation of a permanent 
pacemaker.
• Slow heart that requires implantation of a permanent pacemaker.
The study will aim to enrol 80 patients at the Liverpool cardiothoracic centre.
5. Do I have to take part?
It is up to you to decide whether or not to take part. You have been given this 
information sheet to help you make a decision. If you do decide to take part you 
will be asked to sign a consent form. If you decide to take part you are still free 
to withdraw at any time and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care and 
medical treatment you receive.
6. What will happen to me if I take part?
If you decide to take part you will have a pacemaker implanted with the
right ventricular lead placed either in the RVA or RVOT position. A
computer programme will determine your allocation to either group. This method 
of allocation has been shown to be the most reliable and fair way of comparing 
two different treatments. With this randomisation procedure 50% of patients will 
be chosen for RVA pacing and 50% will be chosen for RVOT pacing. Patients 
will be assessed twice, at 6 months and 18 months. All other aspects of the 
procedure and subsequent care will follow our routine practice for pacemaker 
implantation.
Participation in this study will involve the performance of an echocardiogram 
(heart ultrasound scan) and exercise test (if appropriate) before implantation and 
at 6 and 18 months after the procedure to evaluate how the pacemaker is 
affecting your heart function and your physical fitness. You will also be asked to 
fill out some forms assessing your quality of life. We will also collect some 
limited information about your health after the pacemaker implantation from your 
medical records. This information will be kept strictly confidential.
7. What do I have to do?
If you decide to take part there will be no changes to your routine clinical care 
after your pacemaker implantation. There will be no particular lifestyle or dietary 
restrictions over and above those advised for pacemaker patients. Similarly 
there are no extra restrictions concerning driving or sport over and above those 
advised for patients who have had a pacemaker implant.
8. What is the procedure that is being tested?
The procedure being tested is whether elective implantation of RVOT 
pacemaker position is better than the traditional RVA position.
9. What are the alternatives for diagnosis or treatment?
150
If you were not taking part in the study you would also receive either RVA or 
RVOT position pacemaker, but this will be decided by the implanting doctor. The 
echocardiogram and exercise test will not be done routinely.
10. What are the side effects of any treatment received when taking 
part?
The possible side effects are those common to all patients undergoing 
pacemaker implantation procedure. You will be assigned a study nurse or doctor 
whom you can contact in case you have any concerns or questions about the 
study.
11. What are the possible disadvantages and risks of taking part?
The possible disadvantages and risks of taking part are common to all patients 
undergoing any permanent pacemaker implantation procedure. There is no 
greater risk from implantation of the pacemaker lead at the RVOT compared to 
the RVA.
12. What are the possible benefits of taking part?
The possible benefits of having a pacemaker inserted at the RVOT position as 
compared to the traditional RVA position is a possible reduction in the risk of 
developing heart failure. However it is not possible to say definitively whether it 
is better to have a pacemaker inserted at the RVOT position as compared to the 
traditional RVA position at the present time. By taking part you may help us to 
decide the best position in the future for treating patients requiring permanent 
pacemaker implantation.
13. What if new information becomes available?
Sometimes during the course of a research project, new information becomes 
available about the treatment that is being studied. However if some, as yet 
unknown, significant new information came to light that had a bearing on the 
study and your participation, this would be considered by the committee of 
experts who oversee the conduct of all the studies conducted at cardiothoracic 
Centre and you will be informed of the outcome.
14. What happens when the research study stops?
When the study is completed you will not be required to continue with any study 
procedures and your care will continue as usual.
15. What if something goes wrong?
If taking part in this research project harms you, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, 
then you may have grounds for a legal action as in all NHS care. Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms will be available to you.
16. Will my taking part in this study be kept confidential?
If you consent to take part in the research, members of staff at the Clinical Trials 
Unit of the Cardiothoracic Centre may inspect your medical records to ensure 
that the data is accurate for the purpose of analysing the results. Your records 
may also be looked at by people from the regulatory authorities or other NHS 
staff to check that the study is being carried out correctly.
All information that is collected about you during the course of the research will 
be kept strictly confidential.
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17. What will happen to the results of the research study?
When the study is completed and the data analysed a manuscript will be 
submitted for publication. You will also able to request a copy of any publications 
of the results from this study. The results will be presented at medical 
conferences and published in medical journals. Your identity will not be divulged 
in any presentation, publication or report.
18. Who is organising and funding the research?
The project is funded by the Liverpool Cardiothoracic NHS Trust and charitable 
funds. A Steering Committee of experts in heart disease and research 
methodology will oversee the conduct of the study. The study will be co­
ordinated by the Clinical Trials Unit, Liverpool Cardiothoracic NHS Trust. Your 
doctor is not being paid for you to participate in the SSP-1 pacemaker study 
although some funding is provided for staff to help run the study at your hospital.
19. Who has reviewed the study?
National ethics approval has been obtained for this study and your hospital’s 
Ethics Committee have reviewed the study.
20. Contact for Further Information
Thank you for taking time to read this patient information sheet. If you decide to 
take part we will ask you to sign a consent form. You will be given a copy of the 
signed consent form and the patient information sheet.
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives more information about medical research 
and looks at some questions potential recruits may want to ask. You may obtain 
copies from CERES, PO Box 1365, London N16 OBW.
The doctors and nurses involved in this study will be pleased to discuss any 
questions or concerns you may have. If you do have any questions or concerns 
about the study please contact:
Principal Investigator: Dr D Jay Wright 
Tel: 0151 293 2457 (sec)
Email: David.Wright@ctc.nhs.uk 
Local Study Co-ordinator: Dr Khaled Albouaini 
Tel: 0151 2281616, mobile 07815107165 
Email: khaled.albouaini@ctc.nhs.uk
Thank you very much.
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Appendix 3
The Cardiothoracic Centre - Liverpool
________________________________________________________NHS Trust________
PATIE NfT DETAILS
1 Date of screening (dd/mm/yyyy) / /
2 Patient’s name Initials :
3 D.O.B. / Gender / / Male/Female
4 Hospital / Unit number
5 Address: House no./Street
6 City
7 Postal code
8 Country
9 Telephone number
10 NHS number
11 Consultant in charge DMT [ ] JEPW [ ]
DETAILS OF RELATIVE OR FRIEND NOT AT THE SAME ADDRESS
12 Relative’s or friend’s name
13 Address: House no./Street
14 City
15 Postal code
16 Country
17 Telephone number
DETAILS OF G.P.
18 GP name
19 Surgery name
20 Address: Street
21 City
22 Postal code
23 Country
24 Telephone number
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BASELINE CHARACTERISTICS
MEDICAL HISTORY
25 Has the patient been listed for ablation Yes [ ] No [ ]
26 Hypertension treated with drugs Yes [ ] No [ ]
27 Hyperlipidemia treated with drugs Yes [ ] No [ ]
28 Diabetes Yes [ ] No [ ]
29 Smoking status Yes [ ] No [ ]
30 COPD requiring treatment Yes [ ] No [ ]
31 Asthma requiring treatment Yes [ ] No [ ]
32 Documented Peripheral Arterial Yes [ ] No [ ]
33 Any previous mediastinal Yes [ ] No [ ]
34 Prior CVA, if yes date (mm/yyyy) Yes [ ] / No [ ]
35 Prior MI, if yes date (mm/yyyy) Yes [ ] / No [ ]
36 Prior PTCA ± stent, if yes date Yes [ ] / No [ ]
37 Other cardiovascular intervention, if 
ves date (mm/ww)
Yes [ ] ___/__________ No[ ]
38 If yes, specify type of intervention CABG ] Valve surgery [ ]
39 Congestive Heart failure, if yes date
(mm/vvvvl
Yes [ ] / | No[ ]
40
Physical disability preventing exercise
test Yes [ ]
No [ ]
CLINICAL EXAMINATION
41 Height (cm) / Weight (kg) . cm |. kg
42 BMI
43 Ethnic origin
44 NYHA class I II III IV
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MEDICATIONS AT BASELINE
45 Aspirin Yes [ ] No [ ]
46 Clopidogrel Yes [ ] No [ ]
47 If either above is yes, days before No. of days =
48 Warfarin Yes [ ] No [ ]
49 Other anticoagulant Yes [ ] No [ ]
50 If yes, please specify Phenindione [ ] Sinthrome [ ]
51 Beta-blockers Yes [ ] No [ ]
52 Calcium-channel antagonists Yes [ ] No [ ]
53 Nitrates Yes [ ] No [ ]
54 Potassium channel activators Yes [ No [ ]
55 Lipid lowering agent (tick all that1 \ Statins [ ] Other [ ] No [ ]
56 ACE inhibitors Yes [ ] No [ ]
57 Angiotensin-II antagonists Yes [ ] No [ ]
58 Diuretics Yes [ ] No [ ]
59 Digoxin Yes [ ] No [ ]
60 Amiodarone Yes [ ] No [ ]
61 Any other anti-arrythmic medication Flecainide Propafanone XTa r n[ ] M NA[ 1
ELIGIBILITY CRITERIA
Inclusion Criteria
62 Atrial fibrillation Yes [ ] No [ ]stop
63 Atrial flutter Yes [ ] No [ ] stop
If anv NO. stop - patient should not be randomised
Exclusion Criteria
64 Indication for implantation of ICD Yes [ ] stop No [ ]
65
Indication for biventricular pacemaker
implant Yes [ ] stop No [ ]
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66
Evidence of left or right bundle branch
block Yes [ ] stop No[ ]
67 QRS > 120 ms Yes [ ] stop No [ ]
68
Inability to comply with follow-up
procedures Yes [ ] stop No [ ]
69
Exercise limitation due to pathological 
process i.e. angina, respiratory, 
neurological or rheumatological
Yes [ ] stop No [ ]
70
Significant valvular heart 
disease including indwelling Yes [ ] stop No[ ]
71
Current or recent participation in any 
other clinical investigation Yes [ ]stop No [ ]
72 Life expectancy less than 2 Yes [ ] stop No[ ]
73 Ventricular septal defect Yes [ ] stop No[ ]
74
Undergone CABG or PTCA 
within last 3 months Yes [ ] stop No [ ]
75
Planned angioplasty/cardiac 
surgery Yes [ ] stop No[ ]
If anv YES* stop - patient should not be randomised
CONSENT
76
Has patient been fully informed and 
received a patient information sheet Yes [ ] No [ ]
77 Date of consent (dd/mm/yyyy) / /
78 Name of person obtaining consent
79
Present in casenotes and site
file Yes [ ] No[ ]
QUALITY OF LIFE QUESTIONNAIRE 1 - MINNESOTA SCORE
80 Questionnaire completed
Yes
[ ]
Date
____ /_____ /__
Score No
t ]
81 If no, reason
QUALITY OF LIFE QUESTIONNAIRE 2 - SHORT FORM-36 HEALTH SURVEY
82 Questionnaire completed
Yes
[ ]
Date
____ /_____/_
Score No
t ]
83 If no, reason
BASELINE INVESTIGATIONS
ECG
84
ECG recorded, if yes date 
(dd/mm/yyyy)
Yes 
[ ]
No
[ ]
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85 If yes, rhythm Sinus [ ] AF [ ] Paced [ ]
86 If no ECG, give reason
ECHOCARDIOGRAM
87 Ventricular function measured Yes [ ] No [ ]
88 Date (dd/mm/yyyy) ____/____ /________
89 Ejection fraction (%)
90 Evidence of mitral regurgitation Yes [ ] No [ ]
91 Mitral Regurgitation
Vena
Contracta
r 1
Dp/Dt
[ ]
PISA
[ ]
92 Evidence of aortic valve disease Yes [ ] No[ ]
93
Atrio-ventricular Dysynchrony APE >
140ms Yes [ ] No [ ]
94 Interventricular delay (APE - PPE) > Yes [ ] No [ ]
95 Intraventricular dysynchrony Di>D2 Yes [ ] No [ ]
96 LYOT VT1 (cm)
CARDIOPULMONARY EXERCISE TEST
97 Date of test (dd/mm/yyyy l/
98 Heart rate at rest (bpm)
99 Blood pressure at rest (mm/Hg)
100 VE/VO2 at 1 litre VO2 (litres )
101
VE (ventilation equivalent) minute 
ventilation (litres per min.)
102
RER (respiratory exchange ratio)
attained
103 Peak VO2 (ml/kg/min.)
104
End tidal PC02 <3 (hyperventilation)
(mm/Hg)
105
CO (cardiac output) at rest (litres per
min.)
106 CO on exercise (litres per min.)
107
CPO (cardiac power output) at rest
(watts)
108 CPO on exercise (watts)
109 Cardiac reserve (litres)
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RANDOMISATION
For randomisation please call the following number 
during UK office hours (09.00-17.00 hrs.)
0151 293 2291 or 0151 293 2292
110 Date of randomisation (dd/mm/yyyy) / /
111 Randomisation code
112
Name of person obtaining 
randomisation
113
Proposed date of pacemaker 
implantation (dd/mm/yyyy) ____ /_____ /__________
114 Treatment allocation RVA [ ] RYOT [ ]
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PACEMAKER IMPLANTATION
Details of the procedure
115 Date of admission (dd/mm/yyyy) / /
116 Date of the procedure (dd/mm/yyyy) //
117 Single lead device Yes [ ] No[ ]
118 Device type WI [ ] VVIR [
n
DDD[ ] PDDR[
119 Serial number
120 Lead type Active [ ] Passive [ ]
121 Lead number
122 Total procedure time (mins).
123 AV nodal ablation Yes [ ] No [ ] NA [ ]
124 Programming :Base response rate Yes [ ] No[ ]
125 Upper response rate Yes [ ] No [ ]
126 Hysteresis Yes [ ] No [ ]
PROCEDURAL COMPLICATONS
127 Death Yes [ Date / / No [
T ..... T
128 VT requiring cardioversion Yes [ ] No [ ]
129 Transfusion requirement Yes [ ] No [ ]
130 Cardiac arrest requiring CPR Yes [ ] No [ ]
131 Haematoma requiring evacuation Yes [ ] No [ ]
132 Lead displacement Yes [ ] No [ ]
133 Pneumothorax Yes [ ] No [ ]
INVESTIGATOR’S DECLARATION
I declare that the information presented in the Case Record Form (page 7) accurately reflects 
the procedural details/complications within the medical records.
134 Name of person completing form
135 Signature of person completing form
136 Date form completed (dd/mm/yyyy) / /
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FOLLOW UP AT 6 MONTHS FOLLOWING PROCEDURE
QUALITY OF LIFE QUESTIONNAIRE X - MINNESOTA SCORE
1 Questionnaire completed
Yes
[ ]
Date
____ /_____/_____
Score No
[ ]
2 If no, reason
QUALITY OF LIFE QUESTIONNAIRE 2 - SHORT FORM-36 HEALTH SURVEY
3 Questionnaire completed
Yes
[ ]
Date
____ /_____/_____
Score No
[ ]
4 If no, reason
MEDICATIONS
5 Aspirin Yes [ ] No [ ]
6 Clopidogrel Yes [ ] No [ ]
7
If either above is yes, days before 
intervention that they were stopped No. of days =
8 Warfarin Yes [ ] No [ ]
9 Other anticoagulant Yes [ ] No [ ]
10 If yes, please specify Phenindione [ ] Sinthrome [ ]
11 Beta-blockers Yes [ ] No [ ]
12 Calcium-channel antagonists Yes [ ] No [ ]
13 Nitrates Yes [ ] No [ ]
14 Potassium channel activators Yes [ ] No [ ]
15 Lipid lowering agent (tick all that- ..t \ Statins [ ] Other [ ] No[ ]
16 ACE inhibitors Yes [ ] No [ ]
17 Angiotensin-II antagonists Yes [ ] No[ ]
18 Diuretics Yes [ ] No[ ]
19 Digoxin Yes [ ] No[ ]
20 Amiodarone Yes [ ] No [ ]
21 Any other anti-arrythmic medication Flecainide Propafanone
[ ] [ ]
NA [ ]
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INVESTIGATIONS
ECG
22 ECG recorded, if yes date 
(dd/mm/yyyy)
Yes / /
[ 1
No 
[ ]
23 If yes, rhythm Sinus [ ] AF[ ] Paced [ ]
24 If no ECG, give reason
ECHOCARDIOGRAM
25 Ventricular function measured Yes [ ] No [ ]
26 Date measured (dd/mm/yyyy / /
27 Ejection fraction (%)
28 Evidence of mitral regurgitation Yes [ ] No [ ]
29 Mitral Regurgitation
Vena
Contracta
r n
Dp/Dt
[ ]
PISA
[ ]
30 Evidence of aortic valve disease Yes [ ] No [ ]
31 Atrio-ventricular Dysynchrony APE> 140ms Yes [ ] No [ ]
32 Interventricular delay (APE - PPE) > 40 ms Yes [ ] No [ ]
33 Intraventricular dysynchrony Di>D2 Yes [ ] No [ ]
34 LVOTVT1 (cm)
CARDIOPULMONARY EXERCISE TEST
35 Date of test (dd/mm/yyyy / /
36 Heart rate at rest (bpm)
37 Blood pressure at rest (mm/Hg)
38
VE/VChat 1 litre V02 (litres)
39
VE (ventilation equivalent) minute 
ventilation (litres per min.)
40
RER (respiratory exchange ratio)
attained
41 Peak VO2 (ml/kg/min.)
42 End tidal PC02 <3 
(hyperventilation) (mm/Hg)
43 CO (cardiac output) at rest (litres per
min.)
44 CO on exercise (litres per min.)
45
CPO (cardiac power output) at rest
(watts)
46 CPO on exercise (watts)
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INVESTIGATOR’S DECLARATION
I declare that the information presented in the Case Record Form (pages 8 to 9) accurately 
reflects the medical records, including the results of tests and evaluations performed on the 
dates snecified.
48 Name of person completing form(capitals)
49 Signature of person completing form
50 Date form completed (dd/mm/yyyy) / /
SERIOUS ADVERSE EVENTS at 6 MONTH FOLLOW UP
51 Death Yes Date / / No
i j [ ]
52 Lead displacement Yes [ ] No [ ]
53 Haematoma Yes [ ] No [ ]
54 Infection Yes [ ] No [ ]
55 Admission to hospital with heart failure Yes [ ] No [ ]
56 S AE reported by (name)
57 Date reported (dd/mm/yyyy) ____ /_____ /__________
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Appendix 4
Minnesota Living With Heart Failure™ Questionnaire
These questions concern how your heart failure (heart condition) has prevented you 
from living as you wanted during the last month. The items listed below describe 
different ways some people are affected. If you are sure an item does not apply to 
you or is not related to your heart failure, then circle 0 (No) and go on to the next 
item. If an item does apply to you, then circle the number rating how much it 
prevented you from living as you wanted.
Visit date:______ /_______/_______
Baseline ___□ 6 months 18 months
Did your heart failure prevent you from living as you 
wanted during the last month by:
No Very
Little
Very
Much
1. Causing swelling in your ankles, legs, etc.? 0 1 2 3 4 5
2. Making you sit or lie down to rest during the day? 0 1 2 3 4 5
3. Making your walking about or climbing stairs difficult? 0 1 2 3 4 5
4. Making your working around the house or yard difficult? 0 1 2 3 4 5 .
5. Making your going places away from home difficult? 0 1 2 3 4 5
6. Making your sleeping well at night difficult? 0 1 2 3 4 5
7. Making your relating to or doing things with your friends or 
family difficult?
0 1 2 3 4 5
8. Making your working to earn a living difficult? 0 1 2 3 4 5
9. Making your recreational past times, sports or hobbies 
difficult?
0 1 2 3 4 5
10. Making your sexual activities difficult? 0 1 2 3 4 5
11. Making you eat less of the foods you like? 0 1 2 3 4 5
12. Making you short of breath? 0 1 2 3 4 5
13. Making you tired, fatigued, or low on energy? 0 1 2 3 4 5
14. Making you stay in a hospital? 0 1 2 3 4 5
15. Costing you money for medical care? 0 1 2 3 4 5
16. Giving you side effects from medication? 0 1 2 3 4 5
17. Making you feel you are a burden to your family or 
friends?
0 1 2 3 4 5
18. Making you feel a loss of self-control in your life? 0 1 2 3 4 5
19. Making you worry? 0 1 2 3 4 5
20. Making it difficult for you to concentrate or remember 
things?
0 1 2 3 4 5
21. Making you feel depressed? 0 1 2 3 4 5
Sub totals :
TOTAL SCORE:
Copyright University of Minnesota 1986
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Appendix 5
Short Form-36 (SF-36) Health Survey
Overview
The Short-Form-36 (SF-36) Health Survey was developed by Dr John 
Ware and was derived from the Rand Corporation's Medical Outcomes 
Study (MOS). It is used as a general survey of health status and an 
outcome measure in clinical practice. It can also be used together with 
disease-specific instruments for patient evaluation. The survey may be 
self-administered or may be completed by an interviewer.
Instructions for self-administration:
This survey asks for your views about your health. This information will 
help keep track of how you feel and how well you are able to do your 
usual activities. Answer every question by marking the answer as 
indicated. If you are unsure about how to answer a question please give 
the best answer you can.
1. In general would you say your health is?
• Excellent [1]
• Very good [2]
• Good [3]
• Fair [4]
• Poor [5]
2. Compared to one year ago how would you rate your health in 
general now?
• Much better now than one year ago [1]
• Somewhat better now than one year ago [2]
• About the same now as one year ago [3]
• Somewhat worse now than one year ago [4]
• Much worse now than one year ago [5]
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3. The following items are about activities you might do during a 
typical day. Does your health now limit you in these activities?
If, so how much?
Responses
• Yes limited a lot m
• Yes limited a little [2]
• No not limited at all [3]
a. Vigorous activities such as running lifting heavy objects 
participating in strenuous sports. [1] [2] [3]
b.
c.
d.
e.
f.
g
h.
i.
Moderate activities such as moving a table pushing a vacuum
cleaner bowling or playing golf. [1]. ...[2]....[3]....
Lifting or carrying groceries. m. ...[2].. ..[3]....
Climbing several flights of stairs. [1].. .. [2].. ..[3]....
Climbing one flight of stairs. [i].. ..[2]... . [3]....
Bending kneeling or stooping. 1].....[2].... [3]....
Walking more than one mile. [i].. ..[2].. ..[3]....
Walking several blocks. [1].. ..[2]... .[3]....
Bathing or dressing yourself. [1]..,..[2],. •■[3].....
4. During the past 4 weeks have you had any of the following 
problems
with your work or other regular daily activities as a result of your 
physical health?
Responses
•Yes [1]
•No [2]
a. Cut down on the amount of time you spent on work or other activities.
b. Accomplished less than you would like. [1]....[2]....
c. Were limited in the kind of work or other activities. [1],...[2]....
d. Had difficulty performing the work or other activities (for example it took 
extra effort). [1]....[2]....
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5. During the past 4 weeks have you had any of the following 
problems with your work or other regular activities as a result of 
any emotional problems (such as feeling depressed or anxious)?
Responses
•Yes [1]
• No [2]
a. Cut down on the amount of time you spent on work or other activities.
b. Accomplished less than you would like. [1]....[2]....
c. Didn't do work or other activities as carefully as usual. [1]....[2]....
6. During the past 4 weeks to what extent has your physical health 
or emotional problems interfered with your normal social activities 
with family friends, neighbours or groups?
•Not at all [1]
• Slightly [2]
• Moderately [3]
• Quite a bit [4]
• Extremely [5]
7. How much bodily pain have you had during the past 4 weeks?
•None [1]
• Very mild [2]
• Mild [3]
• Moderate [4]
• Severe [5]
• Very severe[6]
8. During the past 4 weeks how much did pain interfere with your 
normal work (including both work outside the home and 
housework)?
•Not at all [1]
• A little bit [2]
• Moderately [3]
• Quite a bit [4]
• Extremely [5]
9. These questions are about how you feel and how things have 
been with you during the past 4 weeks. For each question please 
give the one answer that comes closest to the way you have been 
feeling. How much of the time during the past 4 weeks:
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Responses:
All of the time [1]
Most of the time [2]
A good bit of the time [3]
Some of the time [4]
A little of the time [5]
None of the time [6]
a. Did you feel full of pep?
[1]...[2]...[3]...[4]...[5]...[6]
b. Have you been a very nervous person? 
[1]-.[2]...[3]...[4]...[5]...[6]
c. Have you felt so down in the dumps that nothing could cheer you up?
[1]...[2]...[3]...[4]...[5]...[6]
d. Have you felt calm and peaceful?
[1]...[2]...[3]...[4]...[5]...[6]
e. Did you have a lot of energy?
[1]...[2]...[3]...[4]...[5]...[6]
f. Have you felt downhearted and blue?
[1]...[2]...[3]...[4]...[5]...[6]
g. Did you feel worn out?
[1]...[2]...[3]...[4]...[5]...[6]
h. Have you been a happy person?
[1]...[2]...[3]...[4]...[5]...[6]
i. Did you feel tired?
[1]...[2]...[3]...[4]...[5]...[6]
10. During the past 4 weeks how much of the time has your physical 
health or emotional problems interfered with your social activities 
(like visiting with friends relatives etc.)?
• All of the time [1]
• Most of the time [2]
• Some of the time [3]
• A little of the time [4]
• None of the time [5]
11. How TRUE or FALSE is each of the following statements for 
you?
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Responses
• Definitely true [1]
• Mostly true [2]
• Don't know [3]
• Mostly false [4]
• Definitely false [5]
a. I seem to get sick a little easier than other people.
b. I am as healthy as anybody I know.
[1]...[2]...[3]..,[4]...[5]..,
c. I expect my health to get worse.
[1]...[2]...[3]...[4]...[5]...
d. My health is excellent.
[1]...[2]...[3]...[4]...[5]..,
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE.
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